View Filing Data

DOCUMENT AND ENTITY INFORMATION - shares	3 Months Ended
DOCUMENT AND ENTITY INFORMATION - shares	Jan. 31, 2013	Mar. 19, 2013
Entity Registrant Name	ADVAXIS, INC.
Entity Central Index Key	0001100397
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	adxs
Entity Common Stock, Shares Outstanding		536,492,002
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jan. 31, 2013
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2013

BALANCE SHEETS - USD ($)	Jan. 31, 2013	Oct. 31, 2012
ASSETS
Cash	$ 100	$ 232
Prepaid Expenses	11,671	25,798
Other Current Assets	83,182	8,182
Deferred Expenses - current	874,187	860,293
Total Current Assets	969,140	894,505
Deferred expenses - long term	253,170	342,007
Property and Equipment (net of accumulated depreciation)	73,476	78,068
Intangible Assets (net of accumulated amortization)	2,418,762	2,413,755
Deferred Financing Cost (net of accumulated amortization)	37,233	49,024
Other Assets	38,438	38,438
TOTAL ASSETS	3,790,219	3,815,797
LIABILITIES AND SHAREHOLDERS' DEFICIENCY
Accounts payable	3,883,771	5,155,797
Accrued expenses	1,050,841	1,367,412
Short term convertible notes and fair value of embedded derivative	2,190,205	2,089,099
Notes Payable - Officer	490,595	477,274
Notes payable - other	250,000	250,000
Total Current Liabilities	7,865,412	9,339,582
Deferred Rent	0	4,803
Long-term Convertible Note (less unamortized OID of $40,566)	403,438	0
Common Stock Warrant Liability	3,384,725	434,136
Total Liabilities	11,653,575	9,778,521
Shareholders' Deficiency:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; issued and outstanding 740 at January 31, 2013 and at October 31, 2012. Liquidation preference of $9,907,570	0	0
Common Stock - $0.001 par value; authorized 1,000,000,000 shares, issued and outstanding 493,415,628 at January 31, 2013 and 394,804,165 at October 31, 2012.	493,415	394,804
Additional Paid-In Capital	55,487,126	51,727,921
Promissory Note Receivable	(10,534,424)	(10,484,022)
Deficit accumulated during the development stage	(53,309,473)	(47,601,427)
Total Shareholders' Deficiency	(7,863,356)	(5,962,724)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIENCY	$ 3,790,219	$ 3,815,797

BALANCE SHEETS [Parenthetical] - USD ($)	Jan. 31, 2013	Oct. 31, 2012
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	493,415,628	394,804,165
Common stock, shares outstanding	493,415,628	394,804,165
Series B Preferred Stock [Member]
Preferred stock, shares issued	740	740
Preferred stock, shares outstanding	740	740
Liquidation preference	$ 9,907,570	$ 9,722,570

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		131 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013
Revenue	$ 0	$ 0	$ 1,863,343
Operating Expenses
Research and Development Expenses	979,103	2,212,909	30,781,937
General and Administrative Expenses	1,201,951	1,031,392	28,070,461
Total Operating expenses	2,181,054	3,244,301	58,852,398
Loss from Operations	(2,181,054)	(3,244,301)	(56,989,055)
Other Income (expense):
Interest expense	(361,176)	(1,616,882)	(15,347,041)
Other Income (expense)	(19,898)	6,744	239,811
(Loss) Gain on note retirement	152,491	(697,642)	(840,451)
Net changes in fair value of common stock warrant liability and embedded derivative liability	(4,023,599)	839,750	17,018,697
Net Loss before benefit for income taxes	(6,433,236)	(4,712,331)	(55,918,039)
Income tax benefit	725,190	346,787	2,652,450
Net Loss	(5,708,046)	(4,365,544)	(53,265,589)
Dividends attributable to preferred shares	185,000	185,000	2,507,570
Net Loss applicable to Common Stock	$ (5,893,046)	$ (4,550,544)	$ (55,773,159)
Net Loss per share, basic and diluted (in dollars per share)	$ (0.01)	$ (0.02)
Weighted average number of shares outstanding, basic and diluted (in shares)	445,628,988	262,831,912

STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		131 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013
OPERATING ACTIVITIES
Net loss	$ (5,708,046)	$ (4,365,544)	$ (53,265,589)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash charges to consultants and employees for options and stock	369,923	300,184	5,349,969
Amortization of deferred financing costs	15,291	14,825	354,115
Amortization of discount on convertible promissory notes	7,979	532,559	2,718,356
Impairment of intangible assets	0	0	26,087
Non-cash interest expense	328,187	1,060,699	11,822,199
(Gain) Loss on change in value of warrants and embedded derivative	4,023,599	(839,750)	(17,018,697)
Warrant Expense	3,274	0	767,634
Settlement Expense	131,965	0	396,965
Employee Stock Purchase Plan	5,481	0	23,782
Value of penalty shares issued	0	0	149,276
Depreciation expense	4,592	0	214,040
Amortization expense of intangibles	38,703	35,409	781,345
Write off of intangible assets	0	0	33,211
Interest Income	0	0	267
Loss (Gain) on note retirement	(152,491)	697,642	840,451
Changes in operating assets and liabilities :
Decrease (Increase) in prepaid expenses	14,128	23,389	(11,669)
(Increase) in other current assets	(75,000)	(80,961)	(83,182)
(Increase) in other assets	0	0	(132,271)
(Increase) decrease in deferred expenses	74,943	28,455	(619,629)
Increase (decrease) in accounts payable and accrued expenses	(225,360)	470,238	12,278,900
(Decrease) in deferred rent	(4,803)	(14,410)	0
Increase in interest payable	9,530	8,257	2,232
Net cash used in operating activities	(1,138,105)	(2,129,008)	(35,372,208)
INVESTING ACTIVITIES
Cash paid on acquisition of Great Expectations	0	0	(44,940)
Purchase of property and equipment	0	0	(241,937)
Cost of intangible assets	(43,709)	(126,375)	(3,264,354)
Net cash used in Investing Activities	(43,709)	(126,375)	(3,551,231)
FINANCING ACTIVITIES
Proceeds from convertible notes	753,500	1,451,963	18,612,900
Repayment of convertible notes	0	(52,941)	(1,649,030)
Payment of deferred offering expenses	(3,500)	(28,500)	(117,500)
Cash paid for deferred financing costs	0	0	(584,493)
Proceeds from notes payable	0	0	250,000
Proceeds from (Repayment of) Officer Loan	3,800	(35,000)	318,285
Net proceeds from issuance of Preferred Stock	0	0	8,610,499
Payment on cancellation of warrants	0	0	(600,000)
Proceeds from exercise of warrants	0	411,765	1,666,766
Net proceeds of issuance of common stock	427,882	0	12,416,112
Net cash provided by Financing Activities	1,181,682	1,747,287	38,923,539
Net increase (decrease) in cash	(132)	(508,096)	100
Cash at beginning of period	232	1,096,538	0
Cash at end of period	$ 100	$ 588,442	$ 100

Supplemental Disclosures of Cash Flow Information - USD ($)	3 Months Ended		131 Months Ended
	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013
Cash paid for Interest	$ 188	$ 44,292	$ 788,205
Cash paid for Taxes	0	2,080	16,453
Supplemental Schedule of Non-cash Investing and Financing Activities
Equipment acquired under notes payable	0	0	45,580
Common stock issued to Founders	0	0	40
Notes payable and accrued interest converted to Preferred Stock	0	0	15,969
Stock dividend on Preferred Stock	0	0	43,884
Accounts Payable from consultants settled with Common Stock	0	0	51,978
Notes payable and embedded derivative liabilities converted to Common Stock	765,599	0	9,407,969
Intangible assets acquired with notes payable	0	0	360,000
Intangible assets acquired with common stock	0	0	70,000
Debt discount in connection with recording the original value of the embedded derivative liability		200,569	6,473,385
Allocation of the original secured convertible debentures to warrants	0	0	214,950
Allocation of the warrants on convertible notes as debt discount		651,846	2,710,406
Cancellation of Note Receivable in connection with Preferred Stock Redemption	0	(3,051,000)	(3,051,000)
Note receivable in connection with exercise of warrants	0	1,795,500	9,998,210
Warrants Issued in connection with issuance of Common Stock	0	0	1,505,550
Warrants Issued in connection with issuance of Preferred Stock	$ 0	$ 0	$ 3,587,625

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

3 Months Ended

Jan. 31, 2013

Nature Of Operations and Basis Of Presentation [Abstract]

Nature Of Operations and Basis Of Presentation [Text Block]

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Advaxis Inc. (the “Company”) is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. The Company’s platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations.

Since the Company’s inception in 2002, it has focused its initial development efforts upon immunotherapies targeting cervical cancer, its predecessor condition, cervical intraepithelial neoplasia, head and neck cancer, breast cancer, prostate cancer, and other cancers and infectious diseases. Although no products have been commercialized to date, research and development and investment continue to be placed behind the pipeline and the advancement of this technology. Pipeline development entails risk and expense. It is anticipated that ongoing operational costs for the Company will continue to increase significantly due to several ongoing clinical trials in this fiscal year.

Liquidity and Financial Condition

The Company’s products are being developed and have not generated significant revenues. As a result, the Company has suffered recurring losses and its liabilities exceed its assets. These losses are expected to continue for an extended period of time. The Company intends to continue raising funds through the sale of both debt and equity in order to continue funding ongoing clinical trials. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. There is a working capital deficiency, a shareholders’ deficiency and recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amount and classification of recorded assets and liabilities should the Company be unable to continue operations. Management’s plans are to continue to raise additional funds through the sales of debt or equity securities. Subsequent to January 31, 2013, the Company raised an aggregate of approximately $1.7 million in additional capital through the sale of equity securities and exercise of warrants.

The Company recognizes it will need to raise additional capital over and above the amount raised subsequent to January 31, 2013 in order to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

Accordingly, the accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily represent realizable or settlement values. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis of Presentation

The accompanying unaudited interim financial statements include all adjustments (consisting only of those of a normal recurring nature) necessary for a fair statement of the results of the interim period. The October 31, 2012 balance sheet is derived from the audited balance sheet included in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2012 (the “Form 10-K”). These interim financial statements should be read in conjunction with the Company’s financial statements and notes for the fiscal year ended October 31, 2012 included in the Form 10-K. The Company believes these financial statements reflect all adjustments and reclassifications that are necessary for a fair presentation of its financial position and results of operations for the periods presented.

Estimates

The preparation of financial statements in accordance with Generally Accepted Accounting Principles (GAAP) involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from estimates.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Jan. 31, 2013

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Revenue from license fees and grants is recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) services have been rendered, (iii) the contract price is fixed or determinable, and (iv) collection is reasonably assured. In licensing arrangements, delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. Since its inception, all of the Company’s revenues have been from multiple research grants. For the three months ended January 31, 2013 and 2012, the Company did not receive any revenue from such grants.

For revenue contracts that contain multiple elements, revenue arrangements with multiple deliverables are divided into separate units of accounting if the delivered item has value to the customer on a standalone basis and there is objective and reliable evidence of the fair value of the undelivered item.

Cash

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of January 31, 2013 and 2012, the Company did not have any cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Net Loss per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the periods. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.

	As of January 31,
	2013		2012
Warrants		125,154,408		140,976,812
Stock Options		44,287,424		45,057,424
Convertible Debt (using the if-converted method)		48,820,627		46,155,102
Total		218,262,459		232,189,338

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

Stock-based compensation for directors is reflected in general and administrative expenses in the statements of operations. Stock-based compensation for employees and consultants could be reflected in research and development expenses or general and administrative expenses in the statements of operations.

Fair Value of Financial Instruments

The carrying amounts of financial instruments, including cash, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Black Scholes valuation model which approximated the binomial lattice options pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.

Debt Discount and Amortization of Debt Discount

Debt discount represents the fair value of embedded conversion options of various convertible debt instruments and attached convertible equity instruments issued in connection with debt instruments. The debt discount is amortized over the earlier of (i) the term of the debt or (ii) conversion of the debt, using the straight-line method which approximates the interest method. The amortization of debt discount is included as a component of other expenses in the accompanying statements of operations.

Recent Accounting Pronouncements

In July 2012, the FASB issued ASU 2012-02, “Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment." This ASU simplifies how entities test indefinite-lived intangible assets for impairment which improve consistency in impairment testing requirements among long-lived asset categories. These amended standards permit an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, these amended standards eliminate the requirement to perform quantitative impairment testing as outlined in the previously issued standards. The guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s financial position and results of operations.

In February 2013, the FASB issued ASU No. 2013-02, "Reporting of Amounts Reclassified Out of Other Comprehensive Income". ASU 2013-02 finalized the reporting for reclassifications out of accumulated other comprehensive income, which was previously deferred, as discussed below. The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. However, they do require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. An entity is also required to present on the face of the financials where net income is reported or in the footnotes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income, but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. Other amounts need only be cross-referenced to other disclosures required that provide additional detail of these amounts. The amendments in this update are effective for reporting periods beginning after December 15, 2012. Early adoption is permitted.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. The Company files tax returns in U.S. federal and state jurisdictions, including New Jersey, and is subject to audit by tax authorities beginning with the year ended October 31, 2009.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References + Details

PROPERTY AND EQUIPMENT

3 Months Ended

Jan. 31, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

3. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	January 31, 2013 (Unaudited)			October 31, 2012
Laboratory Equipment	$	287,518		$	287,518
Accumulated Depreciation		(214,042	)		(209,450	)
Net Property and Equipment	$	73,476		$	78,068

Depreciation expense for the three months ended January 31, 2013 and 2012 and the period from March 1, 2002 (inception) to January 31, 2013 was $4,592, $0 and $214,042, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

INTANGIBLE ASSETS

3 Months Ended

Jan. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Disclosure [Text Block]

4. INTANGIBLE ASSETS

Under the Penn license agreements, the Company is billed actual patent expenses as they are passed through from Penn and are billed directly from our patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:


	January 31, 2013 (Unaudited)			October 31, 2012
License	$	651,992		$	651,992
Patents		2,466,119			2,422,409
Total intangibles		3,118,111			3,074,401
Accumulated Amortization		(699,349	)		(660,646	)
Intangible Assets	$	2,418,762		$	2,413,755

The expirations of the existing patents range from 2014 to 2023 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. No patent applications with future value were abandoned or expired and charged to expense in the three months ended January 31, 2013 or 2012. Amortization expense for licensed technology and capitalized patent cost is included in general and administrative expenses and aggregated $38,703, $35,409 and $781,345 for the three months ended January 31, 2013 and 2012 and for the period from March 1, 2002 (inception) to January 31, 2013, respectively.

Estimated amortization expense for the next five years is as follows:

Year ended October 31,
2013			105,000
2014			140,000
2015			140,000
2016			140,000
2017			140,000

ACCRUED EXPENSES:

3 Months Ended

Jan. 31, 2013

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

5. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses:

	January 31, 2013 (Unaudited)		October 31, 2012
Salaries and other compensation	$	604,980	$	774,001
Clinical Trial		56,468		56,468
Vendors		77,512		77,512
Consultants		32,200		32,200
Financing costs		159,970		174,970
Legal		41,165		214,902
Interest Payable		55,046		28,859
Other		23,500		8,500
	$	1,050,841	$	1,367,412

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE

3 Months Ended

Jan. 31, 2013

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

6. SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE

Convertible Notes payable consist of the following:

	January 31, 2013 (Unaudited)		October 31, 2012
October 2011 Note Financing		-		58,824
December 2011 Note Financing		-		131,928
May 2012 Note Financing		807,960		588,313
Bridge Notes		62,882		185,758
JMJ Financial		427,730		73,590
Hanover Holdings Note		280,034		362,791
Magna		-		333,086
Chris French		-		25,950
Asher		426,173		150,687
Yvonne Paterson		-		103,804
James Patton		185,426		78,909

Total Convertible Notes		2,190,205		2,093,640

Unamortized discount – Original Issue Discount (OID)		-		(4,541	)


Current Portion of Convertible Notes		2,190,205		2,089,099

October 2011 Note Financing

The notes issued by the Company in the offering completed in October 2011, which we refer to as the October 2011 Notes, matured on October 31, 2012. At October 31, 2012, there was one remaining October 2011 Note with an outstanding principal balance of $58,824.

During the three months ended January 31, 2013, pursuant to the terms of an Assignment Agreement, the Company delivered a convertible note, which we refer to as the Second Magna Exchange Note, to Magna Group, LLC, an affiliate of Hanover, which we refer to as Magna, in an aggregate principal amount of $58,824, convertible into shares of common stock, which bears interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity.

During the three months ended January 31, 2013, the Company converted the $58,824 in principal into 2,277,992 shares of our common stock at conversion prices ranging from $0.025287 to $0.026017, recording non-cash expense of approximately $70,000 to the loss on retirement account, on the statement of operations, for the difference between the amount of the principal converted and the fair value of the shares issued as a result of the conversion.

December 2011 Note Financing

At October 31, 2012, there was one remaining note that was issued by the Company in the offering completed in December 2011, which we refer to as the December 2011 Note, with an outstanding principal balance of $158,824, having an unamortized debt discount of $26,896.

During the three months ended January 31, 2013, pursuant to the terms of an Assignment Agreement, we delivered a convertible note to Magna in an aggregate principal amount of $170,589 (including the above $158,824 and a junior subordinated convertible promissory note in the amount of $11,765), convertible into shares of common stock, which bears interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity.

Accretion of the discount was $28,896 for the three months ended January 31, 2013, resulting in the December 2011 Note being recorded at its principal value of $158,824, on the balance sheet, prior to its assignment. During the three months ended January 31, 2013, the Company converted the $170,589 in principal into 6,110,944 shares of our common stock at a conversion price of $0.027915, recording non-cash expense of approximately $104,000 to the loss on retirement account, on the statement of operations, for the difference between the amount of principal converted and the fair value of the shares issued as a result of the conversion.

May 2012 Note Financings

Effective May 14, 2012, the Company entered into a Note Purchase Agreement, which we refer to as the May 2012 Notes, in which investors acquired $953,333 of our convertible promissory notes for an aggregate purchase price of approximately $715,000 in cash, representing an original issue discount of 25%. The May 2012 Notes are convertible into shares of our common stock at $0.15 per share. Additionally, investors received warrants, which the Company refers to as the May 2012 Warrants, to purchase such number of shares of our common stock equal to 50% of the number of shares of our common stock that would be issuable upon conversion of their May 2012 Notes at an exercise price of $0.15 per share. The May 2012 Notes mature on May 18, 2013. The Company may redeem the May 2012 Notes under certain circumstances. The May 2012 Warrants are exercisable at any time on or before May 18, 2017. The May 2012 Warrants may be exercised on a cashless basis under certain circumstances. As of January 31, 2013 the conversion price of the May 2012 Notes was $.0253 due to the anti-dilution provisions contained therein and the exercise price of the May 2012 Warrants was $.085 as a result of the price reset provisions contained therein.

The Company elected to apply the fair-value option to account for the May 2012 Notes and have recorded the May 2012 Notes at a fair value of $454,680 upon issuance. Unrealized losses on the mark-to-market of the May 2012 Notes which amounted to $681,383 for the period from the date of issuance or May, 14, 2012 through January 31, 2013 were recognized as a non-cash expense in the changes in fair value account on the statement of operations. Accretion of the discount, related to the original fair value of the associated warrants, was recognized through interest expense, amounting to $146,898 for the period from the date of issuance or May 14, 2012 through January 31, 2013.

In addition, as a result of the reset provisions discussed above, the May 2012 Warrants which have been recorded at a fair value of $291,400 on May 14, 2012, are being reflected as a warrant liability as of the date of issuance. At October 31, 2012, the warrant liability amounted to $112,487. As of January 31, 2013, the warrant liability amounted to $193,327, which resulted in a non-cash expense of approximately $80,840 for the three months ended January 31, 2013 and was recorded in the changes in fair value account on the statement of operations.

During the three months ended January 31, 2013, the Company converted $475,000 in principal into 18,784,353 shares of our common stock at a conversion price of $0.025287, recording non-cash expense of approximately $25,000 to the loss on retirement account, on the operations, for the difference between the amount of the principal converted and the fair value of the shares issued as a result of the conversion.

As of January 31, 2013, approximately $478,000 in principal remained outstanding on the May 2012 Notes.

Junior Subordinated Convertible Promissory Notes

The Company refers to all Junior Subordinated Convertible Promissory Notes as “Bridge Notes”.

The Bridge Notes are convertible into shares of the Company’s common stock at a fixed exercise price. For every dollar invested in the Company’s Bridge Notes, each investor received warrant coverage ranging from approximately 23% to 75%, subject to adjustments upon the occurrence of certain events as more particularly described below and in the form of warrant. As of October 31, 2012, substantially all of the Bridge Warrants had an exercise price of $0.15 per share. The Bridge Notes may be prepaid in whole or in part at the option of the Company without penalty at any time prior to the maturity date. The warrants may be exercised on a cashless basis under certain circumstances.

As of October 31, 2012, the Company had approximately $186,000 in principal outstanding on its junior subordinated convertible promissory notes with maturity dates ranging to May 12, 2012.

During the three months ended January 31, 2013, pursuant to the terms of various Assignment Agreements, the Company delivered convertible notes to Magna in aggregate principal amounts of $170,589 (including $11,765 of junior subordinated convertible promissory notes plus the above December 2011 Note in the principal amount of $158,824) and $111,111(consisting of one junior subordinated convertible promissory note), convertible into shares of common stock, which bears interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity. The Company converted the exchange note, which we refer to as the Third Magna Exchange Note, in the principal amount of $111,111 into 4,280,090 shares of our common stock at a conversion price of $0.02596 per share, recording non-cash expense of approximately $106,000 to the loss on retirement account, on the statement of operations, for the difference between the amount of the principal converted and the fair value of the shares issued as a result of the conversion.

As of January 31, 2013, approximately $63,000 in principal remained outstanding on the junior unsubordinated convertible promissory notes, with maturity dates ranging to October 22, 2011. These notes are currently in default and are recorded as current liabilities on our balance sheet at January 31, 2013.

JMJ Financial

On August 27, 2012, in a private placement pursuant to a Note Purchase Agreement, we issued JMJ Financial a convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000, which we refer to as the JMJ August 2012 Note. As of October 31, 2012, the JMJ August 2012 Note remained outstanding. Due to the conversion feature into a variable number of shares, the JMJ August 2012 Note is valued at fair value at each reporting period. As of October 31, 2012, the fair value of the JMJ August 2012 Note was $73,590.

During the three months ended January 31, 2013, the Company converted the JMJ August 2012 Note totaling $100,000 into 3,092,973 shares of our common stock. The Company recorded non-cash income of approximately $96,000 upon conversion. This non-cash income was recorded to the gain on retirement account, on the statement of operations, representing the difference between the fair value of the JMJ August 2012 Note, as reported on the balance sheet, and the fair value of the shares issued as a result of the conversion.

On December 28, 2012, in a private placement pursuant to a note purchase agreement, we issued JMJ Financial a one month convertible promissory note, which we refer to as the JMJ December 2012 Note, in the aggregate principal amount of $100,000 for a purchase price of $100,000. If repaid before January 31, 2013, the principal amount of the JMJ December 2012 Note would be $125,000. If the JMJ December 2012 Note was to be rolled into a future financing, the principal amount would be $115,000.

As of January 31, 2013, the JMJ December 2012 Note remained outstanding. The JMJ December 2012 Note is initially convertible at a per share conversion price equal to 70% of the lowest closing price in the 25 days prior to conversion. In recording the JMJ December 2012 Note, at fair value, as of January 31, 2013, the Company recorded non-cash expense of approximately $328,000. Due to the conversion feature into a variable number of shares the JMJ December 2012 Note is valued at fair value at each reporting period. As of January 31, 2013, the fair value of the JMJ December 2012 Note was $427,730. Because the JMJ December 2012 Note matures within one year, it has been classified as a current liability on the balance sheet as of January 31, 2013.

Hanover Holdings Notes

On September 19, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued Hanover Holdings I, LLC, which the Company refers to as Hanover, a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which the Company refers to as the Initial Hanover PIPE Note. On October 19, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which the Company refers to as the Second Hanover PIPE Note, which, together with the Initial Hanover PIPE Note the Company refers to as the Hanover PIPE Notes.

On December 6, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000, which the Company refers to as the Hanover December 2012 Note. The Hanover December 2012 Note bears interest at a rate of 12% per annum, which interest accrues, but does not become payable until maturity or acceleration of the principal of such Hanover December 2012 Note. The Hanover December 2012 Note is convertible into shares of our common stock at a conversion price of $0.03 per share.On December 5, Hanover exchanged the Initial Hanover PIPE Notes for convertible notes in the form of the Hanover December 2012 Note in all material respects (other than date of issuance, exchange date, the maturity date of May 19, 2012 solely with respect to the exchanged Hanover PIPE Note issued in exchange for the Initial Hanover PIPE Note and the maturity date of June 19, 2013 solely with respect to the exchanged Hanover PIPE Note issued in exchange for the Second Hanover PIPE Note) that also are convertible into shares of our common stock at a conversion price of $0.03 per share, which the Company refers to as the Exchanged Hanover PIPE Notes. In addition, on December 6, 2012, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $100,000, which the Company refers to as the Hanover December 2012 Note. Each of the Hanover December 2012 Note and the Exchanged Hanover PIPE Notes are subject to limitations on conversion if after giving effect to such conversion Hanover would beneficially own more than 4.99% of our common stock.

Due to the fixed conversion price of $0.03, the Company reversed fair value adjustments taken in the period ended October 31, 2012 resulting in the Hanover PIPE Notes being recorded on the balance sheet at principal value. Then, the Company recorded beneficial conversion features in the aggregate principal amount of $122,092 as a discount to these notes. Accretion of the discounts amounted to $37,125 for the three months ended January 31, 2013, resulting in Hanover Notes being recorded at $280,034 on the balance sheet as of January 31, 2012.

Magna Note

As of October 31, 2012, the Magna Exchange Note was recorded at a fair value of $333,086 on the balance sheet.

During the three months ended January 31, 2013, Magna converted the remaining approximately $300,000 in principal into 10,124,026 shares of our common stock at prices ranging from $0.0257 to $0.0331, resulting in non-cash expense for the period of approximately $44,000 resulting from the difference between the amount of principal converted and the fair value of the shares issued as a result of the conversion. As of January 31, 2013, the Magna Exchange Note had been converted in full.

Asher

On September 11, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued Asher Enterprises, Inc, which it refers to as Asher, a convertible promissory note in the aggregate principal amount of $103,500, for a purchase price of $100,000, which it refers to as the Asher Note. The Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Asher Note. The Asher Note is convertible into shares of our common stock at a conversion price equal to 61% of the arithmetic average of the five lowest closing trading prices for the common stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Asher Note matures on June 13, 2013, nine months from its issuance date. The Asher Note may be converted by Asher, at its option, in whole or in part. The Asher Note includes a limitation on conversion, which provides that at no time will Asher be entitled to convert any portion of the Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock as of such date.

Unrealized losses on the mark-to-market of the Asher Note which amounted to $47,187, for the period from the date of issuance were recorded as non-cash expense for the period ended October 31, 2012. Unrealized losses on the mark-to-market of the Asher Note for the three months ended January 31, 2013, amounted to $42,130.

On November 12, 2012, in a private placement pursuant to a note purchase agreement, we issued Asher a convertible promissory note in the aggregate principal amount of $153,500, for a purchase price of $150,000, which we refer to as the Second Asher Note. The Second Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Second Asher Note. The Second Asher Note is convertible into shares of our common stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the common stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Second Asher Note matures on June 13, 2013, nine months from its issuance date. The Second Asher Note may be converted by Asher, at its option, in whole or in part. The Second Asher Note includes a limitation on conversion, which provides that at no time will Asher be entitled to convert any portion of the Second Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock as of such date.

Unrealized losses on the mark-to-market of the Second Asher Note which amounted to $79,856, for the period from the date of issuance were recorded as non-cash expense for the period ended January 31, 2013.

Chris French

During the three months ended January 31 2013, the Company converted principal of $25,000 of a note issued to Chris French plus accrued interest of approximately $633, into 565,847 shares of our common stock at a conversion price of $0.045 per share. In addition, the Company issued a warrant in the amount of 282,924 shares, which expires on October 26, 2015 and revalued the warrant liability, at January 31, 2013, with an exercise price of $0.045, resulting in non-cash expense of approximately $21,000 resulting from the difference between the fair value of the note as shown on the balance sheet plus accrued interest to-date and the fair value of the shares issued as a result of the conversion.

Yvonne Paterson

During the three months ended January 31 2013, the Company converted principal of $100,000 of a note issued to Yvonne Paterson plus accrued interest of approximately $2,532, into 2,263,389 shares of our common stock at a conversion price of $0.045 per share. In addition, the Company issued a warrant in the amount of 1,131,695 shares, which expires on October 26, 2015 and revalued the warrant liability, at January 31, 2013, with an exercise price of $0.045, resulting in non-cash expense of approximately $32,000 resulting from the difference between the fair value of the note as shown on the balance sheet plus accrued interest to-date and the fair value of the shares issued as a result of the conversion.

James Patton

On August 2, 2012, in a private placement pursuant to a Note Purchase Agreement, we issued Dr. James Patton, a member of our board of directors, a convertible promissory note, which we refer to as the Patton Note in the principal amount of $66,667 for a purchase price of $50,000. The Patton Note was issued with an original issue discount of 25%. Dr. Patton paid $0.75 for each $1.00 of principal amount of the Patton Note purchased. The Patton Note is convertible into shares of our common stock at a per share conversion price equal to $0.025287 and is subject to “full ratchet” anti-dilution protection upon certain equity issuances below $0.025287 per share (as may be further adjusted). Additionally, Dr. Patton received a warrant, which we refer to as the Patton Warrant, to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the Patton Note at an exercise price of $0.085 per share. The Patton Note matures on August 2, 2013. We may redeem the Patton Note under certain circumstances. The Patton Warrant is exercisable at any time on or before August 2, 2017. The Patton Warrant may be exercised on a cashless basis under certain circumstances. The Patton Note and the Patton Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Dr. Patton be entitled to convert any portion of the Patton Note or Patton Warrant, to the extent that after such conversion or exercise, as applicable, Dr. Patton (together with his affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock as of such date.

As of January 31, 2013, the Patton Warrants had a fair value of $14,044, resulting in non-cash expense of approximately $6,000 for the three months ended January 31, 2013 resulting from an increase in the Black-Scholes value of the warrant liability. In addition, unrealized losses on the mark-to-market of the note which amounted to approximately $103,000, for the three months ended January 31, 2013, were recorded as non-cash expense.

Accretion of the discount amounted to $3,355, for the three months ended January 31, 2013.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

NOTES PAYABLE-OFFICER:

3 Months Ended

Jan. 31, 2013

Notes Payable Officer [Abstract]

Notes Payable Officer [Text Block]

7. NOTES PAYABLE-OFFICER:

Moore Notes

The Company has agreed to sell senior promissory notes, which we refer to as the Moore Notes, to Mr. Moore, our chief executive officer, from time to time, under an agreement which we refer to as the Moore Agreement. The Moore Notes bear interest at the rate of 12% per annum. Currently, under the terms of the amended and restated Moore Notes, the maturity date is the earlier of (i) the date of consummation of an equity financing in an amount of $6.0 million or more or (ii) the occurrence of any event of default as defined in the Moore Notes. As of October 31, 2012, the Company owed Mr. Moore approximately $477,000 in principal and interest under the Moore Notes.

For the three months ended January 31, 2013, Mr. Moore loaned the Company $3,800 under the Moore Notes. The Company paid Mr. Moore no principal on the Moore Notes for the three months ended January 31, 2013. For the three months ended January 31, 2013 and 2012 as well as the period from inception, the Company recorded interest expense of $9,530, $8,257 and $309,552 respectively. As of January 31, 2013 and October 31, 2012, respectively, the Company was not in default under the terms of the Moore Agreement. The Company intends to repay Mr. Moore when funds are sufficiently available. As of January 31 2013, the Company owed Mr. Moore approximately $491,000 in principal and interest under the Moore Notes.

NOTES PAYABLE-OTHER:

3 Months Ended

Jan. 31, 2013

Other Notes Payable [Abstract]

Other Notes Payable [Text Block]

8. NOTES PAYABLE-OTHER:

JLSI, LLC

On July 21, 2012, the Company received $250,000 from JLSI, LLC in return for issuing a promissory note in the principal amount of $250,000, which bears interest at 33% per annum, compounded annually and which matured on December 31, 2012 (“July 2012 Note”). This note still remains outstanding. The Company has recorded approximately $37,000 in interest related to this promissory note, through December 31, 2012.

On March 10, 2013 the Company entered into an Exchange Agreement with JLSI, LLC to exchange the July 2012 Note in the principal amount of $250,000 plus interest of approximately $37,000 for common stock, par value $.001 per share . On December 31, 2012 the parties agreed to prepare the Exchange Agreement with a fixed conversion price of $.03 per share, the market closing price of the Company’s common stock on December 31,2012. The Company expects to issue 9,561,416 shares during the second fiscal quarter of 2013.

LONG-TERM CONVERTIBLE NOTE

3 Months Ended

Jan. 31, 2013

Debt Disclosure [Abstract]

Long-term Debt [Text Block]

9. LONG-TERM CONVERTIBLE NOTE

Tonaquint Note

On December 13, 2012, the Company entered into an agreement, which the Company refers to as the Tonaquint Purchase Agreement, with Tonaquint, Inc., which the Company refers to as Tonaquint, whereby the Company issued Tonaquint a secured convertible promissory note for the initial principal sum of $890,000, which the Company refers to as the Tonaquint Note. The Tonaquint Note bears interest at a rate of 8% and is due 26 months after its issue date. The Tonaquint Note can be converted at a fixed price of $0.16 per share but is subject to reduction in the event that we issue shares below the conversion price of $0.16 after six months has elapsed after the date of the closing.

On the closing date, Tonaquint (i) funded $400,000 in cash, (ii) issued a secured note in the principal amount of $200,000, which the Company refers to as Note 1, and (iii) issued an additional secured note in the principal amount of $200,000, which the Company refers to as Note 2. Note 1 bears interest at a rate of 5% and is due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 8 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions. Note 2 bears interest at a rate of 5% and is due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 10 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions.

The Company has agreed to make installment payments on the Tonaquint Note beginning 6 months after closing in cash or in stock. If the Company chooses to make installment payments in stock, then such stock will be issued at a price per share equal to 80% of the average of the 5 lowest daily closing bid prices for the common stock during the 20 consecutive trading days prior to the installment date. Tonaquint has the right to receive additional shares if the market price of our common stock is lower than the price per share of our common stock on the installment date.

As of January 31, 2013, the Tonaquint Note was recorded at $444,044, which reflects an Original Issue Discount (OID) discount of 9.1%, pursuant to the terms of the Tonaquint Note, or $44,004. A portion of the OID, in the amount of $3,538, was amortized to interest expense, leaving a remaining OID balance of $40,566, as of January 31, 2013. The Company recorded this note on the balance sheet at $403,438 ($444,004 less unamortized OID of $40,566).

DERIVATIVE INSTRUMENTS

3 Months Ended

Jan. 31, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

10.DERIVATIVE INSTRUMENTS

Warrants

As of January 31, 2013, there were outstanding warrants to purchase 125,154,408 shares of our common stock with exercise prices ranging from $0.045 to $0.17 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange warrants-nonexercisable	$	0.15		34,791,156	October 2014	July 2012 Warrant Exchanges
Common Stock Purchase Warrant	$	0.15		3,578,949	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		1,453,553	October 2014-October 2015	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		2,213,234	January 2015-January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.085		2,777,777	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.1399-0.17		25,400,659	January 2013-April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		46,956	N/A	Vendor & Other
Common Stock Purchase Warrant	$	0.085-0.15		3,735,430	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant		0.045-0.085		1,919,764	October 2015-August 2017	August – September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant		0.15		23,676,930	December 2014	Tonaquint Promissory Note
		Subtotal:		99,594,408
Common Stock Purchase Warrant		TBD (1)		25,560,000	April 2014	Preferred Stock Agreement (4/04/2011)
		Grand Total		125,154,408

(1)

During December 2011, the Company unreserved for issuance shares related to the preferred stock warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

As of October 31, 2012, there were outstanding warrants to purchase 100,322,588 shares of our common stock with exercise prices ranging from $0.053 to $0.17 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange warrants-nonexercisable	$	0.15		34,791,156	October 2014	July 2012 Warrant Exchanges
Common Stock Purchase Warrant	$	0.15		3,578,949	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		1,453,553	October 2014-October 2015	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		2,213,234	January 2015-January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		2,777,777	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.1495-0.17		24,754 ,595	January 2013-April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		46,956	N/A	Vendor & Other
Common Stock Purchase Warrant	$	0.15		3,735,430	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant		0.0530-0.15		1,410,938	October 2015-August 2017	August – September 2012 Convertible Promissory Notes
		Subtotal:		74, 762,588
Common Stock Purchase Warrant		TBD (1)		25,560,000	April 2014	Preferred Stock Agreement (4/04/2011)
		Grand Total		100,322,588

(1)

At both January 31, 2013 and October 31, 2012, the Company had approximately 15.1 million of its outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders’ equity section of the balance sheet. Its equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

As of January 31, 2013, the Company had approximately 110 million of its total 125.1 million outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of January 31, 2013 was approximately $3.4 million. At October 31, 2012, the Company had approximately 85.2 million of its total 100.3 million outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of October 31, 2012, was approximately $0.4 million. In fair valuing the warrant liability, at January 31, 2013 and 2012, the Company used the following inputs in its Black-Scholes Model (BSM Model):

	(Unaudited) January 31, 2013			October 31, 2012

Exercise Price:		$ 0.045-0.17			$ 0.053-0.17

Stock Price		0.072			0.045

Expected term:		84-1769 days			81-1736 days

Volatility %		87.77%-180.89	%		66.51%-146.78	%

Risk Free Rate:		.06%-.26	%		.09-.56	%

Warrant Liability

As of January 31, 2013, the Company had approximately 110 million of its total approximately 125.1 million total warrants classified as liabilities (liability warrants). Of these 110 million liability warrants, approximately 75.2 million warrants are outstanding and 34.8 million warrants are exchange warrants – nonexercisable. The Company utilizes the BSM Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. Approximately 14.0 million of our 110 million liability warrants are subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

As of January 31, 2013 and October 31, 2012, the fair value of the warrant liability was approximately $3.4 million and $434,000, respectively. For the three months ended January 31, 2013 and 2012, the Company reported expense of approximately $2.95 million and income of approximately$0.9 million, respectively, due to changes in the fair value of the warrant liability.

Exercise of Warrants

During the three months ended January 31, 2013, no warrants were exercised by investors. During the three months ended January 31, 2012, investors in the Company exercised 2,745,097 warrants at a price of $0.15 per share, resulting in total proceeds to the Company of approximately $412,000.

Warrants with Anti-Dilution Provisions

Some of our warrants (approximately 14.0 million) contain anti-dilution provisions originally set at $0.20 with a term of five years. As of January 31, 2013, these warrants had an exercise price of approximately $0.14. As of October 31, 2012, these warrants had an exercise price of approximately $0.15. If the Company issues any common stock , except for exempt issuances as defined in the warrant for consideration less than the exercise price then the exercise price and the amount of warrant shares available would be adjusted to a new price and amount of shares per the “ weighted average” formula included in the warrant. The anti-dilution provision requires the Company to issue approximately 901,000 additional warrant shares; and the exercise price to be lowered to a de minimis amount ($0.1399). Any future financial offering or instrument issuance below the current exercise price will cause further anti-dilution and re-pricing provisions in approximately 14.0 million of our total outstanding warrants.

For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $0.1399 and $0.10, weighting the possibility of warrants being exercised at $0.1399 between 40% and 50% and warrants being exercised at $0.10 between 60% and 50%.

As of January 31, 2013, there were outstanding warrants to purchase 90,363,252 shares of our common stock and exchange warrants - nonexercisable to purchase 34,791,156 shares of our common stock with exercise prices ranging from $0.045 to $0.17 per share.

- Definition

The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

STOCK OPTIONS:

3 Months Ended

Jan. 31, 2013

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Stock Options Disclosure [Text Block]

11. STOCK OPTIONS:

The Company has one active stock and cash-based incentive plan, the 2011 Omnibus Incentive Plan, which we refer to as the Incentive Plan, pursuant to which the Company has granted stock options to executive officers, directors, employees and consultants. The Incentive Plan was adopted on August 22, 2011 and approved by the shareholders on September 27, 2011. An aggregate of 20,000,000 shares of our common stock (subject to adjustment by the compensation committee) are reserved and available for delivery under the Incentive Plan. On August 13, 2012, at our annual meeting, shareholders ratified and approved an amendment to our Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan to 45,000,000. As of January 31, 2013, the Company had granted 17,120,000 options to employees and consultants, at an exercise price, of approximately $0.15.

The Incentive Plan supersedes all of the Company’s previous stock option plans, which include the 2004 Stock Option Plan, the 2005 Stock Option Plan and the 2009 Stock Option plan under which the Company had options to purchase 2,381,525, 5,444,000 and 19,341,899 shares of common stock. The terms and conditions of the options outstanding under these plans remain unchanged. As of January 31, 2013, the Company had outstanding options of 44,287,424.

Total compensation cost for our stock plans recognized in the statement of operations for the three months ended January 31, 2013 was approximately $263,000, of which approximately $110,000 was included in research and development expenses and approximately $153,000 was included in general and administrative expenses. For the three months ended January 31, 2012, total compensation cost for our stock plans recognized in the statement of operations was approximately $300,000 of which approximately $135,000 was included in research and development expenses and approximately $165,000 was included in general and administrative expenses, respectively.

The fair value of options granted for the three months ended January 31, 2013 and 2012 amounted to $0 and $2,539,792, respectively.

As of January 31, 2013, there was approximately $1,784,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining average vesting period of 1.75 years.

A summary of changes in the stock option plan for three months ended January 31, 2013 is as follows:

	Number of			Weighted-Average
	Options			Exercise Price
Outstanding at October 31, 2012:		44,807,424		$	0.16
Granted		-		$	0.15
Exercised		-			—
Expired		(520,000	)		0.15
Outstanding at January 31, 2013		44,287,424		$	0.16
Vested and Exercisable at January 31, 2013		31,411,086		$	0.15

2011 Employee Stock Purchase Plan

Our board of directors adopted the Advaxis, Inc. 2011 Employee Stock Purchase Plan, which we refer to as the ESPP, on August 22, 2011, and our shareholders approved the ESPP on September 27, 2011. The ESPP allows employees to purchase common stock of the Company at an 85% discount to the market price on designated exercise dates. Employees were eligible to participate in the ESPP beginning December 30, 2011. 5,000,000 shares of our common stock are reserved for issuance under the ESPP.

During the three months ended January 31, 2013, approximately $8,769 was withheld from employees, on an after-tax basis, in order to purchase approximately 208,000 shares of our common stock in February 2013.During the three months ended January 31, 2012, approximately $2,200 was withheld from employees, on an after-tax basis, in order to purchase 15,862 shares of our common stock in February 2012.

COMMITMENTS AND CONTINGENCIES :

3 Months Ended

Jan. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

12. COMMITMENTS AND CONTINGENCIES

University of Pennsylvania

On May 10, 2010, we entered into a second amendment to the Penn license agreement pursuant to which we acquired exclusive licenses for an additional 27 patent applications related to our proprietary Listeria vaccine technology. As part of this amendment we exercised our option for the rights to seven additional patent dockets, including 23 additional patent applications, at an option exercise fee payable in the form of $35,000 in cash and $70,000 in our common stock (approximately 388,889 shares of our common stock based on a price of $0.18 per share) and agreed to pay historical patent costs incurred by Penn at a cost of approximately $462,000. As of January 31, 2013, the Company owed Penn approximately $592,000 under all licensing agreements.

Numoda

On June 19, 2009 we entered into a Master Agreement and on July 8, 2009 we entered into a Project Agreement with Numoda Corporation, which we refer to as Numoda, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervical cancer and CIN. Numoda will be responsible globally for integrating oversight and logistical functions with the clinical research organizations, contract laboratories, academic laboratories and statistical groups involved. The scope of this agreement covers over three years and is estimated to cost approximately $12.2 million for both trials. Pursuant to the Master Agreement, the Company is permitted to pay a portion of outstanding charges to Numoda in the form of the Company’s common stock and during May 2010, the Company issued 3,500,000 shares of its common stock to an affiliate of Numoda in satisfaction of $350,000 in services rendered by Numoda to the Company under the Master Agreement. The Company has recorded deferred expenses on the balance sheet for this amount and amortizes this amount to expense over the life of the agreement. As the Company is billed by Numoda on a monthly basis, these costs are capitalized to deferred expenses. As the clinical trials progress in terms of patient enrollment and time, the Company reduces the deferred expense balance and recognizes clinical trials expense on the statement of operations. From inception through January 31, 2013, the Company has paid Numoda approximately $7.6 million.

As of January 31, 2013, the Company owed Numoda approximately $586,000, which is recorded in our Accounts Payable.

Numoda- Socius Stock Issuance

On July 24, 2012, the Circuit Court of the 11th Judicial Circuit in and for Miami-Dade County, Florida entered an Order Approving Stipulation for Settlement of Claim, which the Company refers to as the Order, in the matter titled Socius CG II, Ltd. v. Advaxis, Inc. The Order, together with the Stipulation for Settlement Claim, which the Company refers to as the Stipulation, provide for the full and final settlement of Socius’s $2,888,860 claim against the Company ($1.8 million claim from Numoda plus approximately $1 million in transaction related costs) in connection with past due invoices relating to clinical trial services, which the Company refers to as the Claim. Socius purchased approximately $1.8 million of the Claim against us from Numoda Corporation.

Pursuant to the terms of the Order and the Stipulation, the Company issued and delivered to Socius an aggregate of 24,681,069 shares of our common stock for the entire Claim, which are subject to adjustment as described in the Stipulation. During the three months ended January 31, 2013, the Company recorded non-cash income of approximately $615,000 related to the issuance of stock to Socius in settlement of the Claim.

Office & Laboratory Lease

In April 2011, the Company entered into a Sublease Agreement and relocated the current offices and laboratory to an approximately 10,000 square foot leased facility in Princeton, NJ which approximate $21,000 per month plus utilities. Utility costs are estimated to be approximately $7,200 per month and are capped at approximately $10,700 per month. The Company made an initial payment of approximately $54,000 prior to entering the new facility. Approximately $38,000 of the initial $54,000 payment was for the security deposit and was recorded on the balance sheet as a long-term asset. The Sublease Agreement has a termination date of November 29, 2015. The Company expects its annual lease costs to approximate $337,000 per year (approximately $1.02 million in the aggregate) until the termination of this agreement in November 2015.

Other

Pursuant to a Clinical Research Service Agreement, executed in April 2005, the Company is obligated to pay Pharm–Olam International for service fees related to our Phase I clinical trial. As of January 31, 2013, the Company has an outstanding balance of $223,620 on this agreement.

Sale of Net Operating Losses (NOLs)

The Company may be eligible, from time to time, to receive cash from the sale of our Net Operating Losses under the State of New Jersey NOL Transfer Program. In December 2012, the Company received notification that it will receive a net cash amount of approximately $725,000 from the sale of our state NOLs and R&D tax credits for the periods ended October 31, 2010 and 2011. These proceeds were received in January 2013.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SHAREHOLDERS' EQUITY

3 Months Ended

Jan. 31, 2013

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

13. SHAREHOLDERS’ EQUITY

Equity Enhancement Program

On October 26, 2012, we entered into a Common Stock Purchase Agreement, which we refer to as the Hanover Purchase Agreement, with Hanover, which requires Hanover to purchase up to $10.0 million of shares of our common stock over the 24-month term following the effectiveness of the resale registration statement. The purchase price for such shares of common stock will be the higher of (i) the minimum price, which we refer to as the Floor Price, set forth in our notice electing to effect such issuance, and (ii) 90% of the arithmetic average of the five lowest closing sale prices of the common stock during the applicable ten trading day pricing period (or, if less, the arithmetic average of all trading days with closing sale prices in excess of the Floor Price), subject to adjustment. Each trading day with a closing sale price less than the Floor Price is excluded from the calculation of the purchase price and automatically reduces the number of trading days in the applicable pricing period.

In consideration for Hanover’s execution and delivery of the Hanover Purchase Agreement, in connection with the execution and delivery of the Hanover Purchase Agreement, we have issued Hanover 3,500,000 Commitment Fee Shares in November 2012. The Company recognized non-cash expense of approximately $157,000 related to the issuance of the Commitment Fee Shares in the current period. We have also agreed to issue Hanover additional Maintenance Fee Shares of our common stock in the event that no shares of common stock have been purchased or sold pursuant to the Hanover Purchase Agreement during any calendar quarter during the 24 month term per the terms of the Hanover Purchase Agreement.

The Hanover Purchase Agreement provides for indemnification of Hanover and its affiliates in the event that we breach any of our representations and warranties under the Hanover Purchase Agreement.

In connection with the Hanover Purchase Agreement, on October 26, 2012, we entered into a registration rights agreement, which we refer to as the Hanover Registration Rights Agreement, with Hanover, and granted to Hanover certain registration rights related to the Commitment Fee Shares, the Maintenance Fee Shares, and the shares issuable under the Hanover Purchase Agreement. Under the Hanover Registration Rights Agreement, we filed with the SEC a registration statement for the purpose of registering the resale of the common stock issued to Hanover.

During the three months ended January 31, 2013, the Company sold 11,390,514 shares of our common stock for proceeds totaling $350,632.

Ironridge Settlement

On December 20, 2012, the Superior Court of the State of California for the County of Los Angeles Central District entered an Order for Approval of Stipulation for Settlement of Claims, which we refer to as the Order, in the matter titled Ironridge Global IV, Ltd. vs. Advaxis, Inc. The Order, together with the Stipulation for Settlement of Claims, which we refer to as the Stipulation, dated December 19, 2012, between us and Ironridge Global IV, Ltd., which we refer to as Ironridge, provides for full and final settlement of Ironridge’s $692,761 claim against us in connection with past due invoices relating to attorney fees, which Ironridge purchased pursuant to a Receivable Purchase Agreement, dated December 14, 2012, which we refer to as the Claim. Pursuant to the terms of the Order and the Stipulation, we are obligated to issue 33,389,663 shares of our common stock to settle the $692,761 owed. On December 21, 2012, we issued and delivered to Ironridge 45,000,000 shares of our common stock, par value $0.001 per share. Accordingly, Ironridge returned 11,610,337 shares of our common stock on January 30, 2013.

Series B Preferred Stock Financing

On July 19, 2010, the Company entered into a Series B Preferred Stock Purchase Agreement with Optimus (the “Series B Purchase Agreement”), pursuant to which Optimus agreed to purchase, upon the terms and subject to the conditions set forth therein and described below, up to $7.5 million of the Company’s newly authorized, non-convertible, redeemable Series B preferred stock (“Series B Preferred Stock”) at a price of $10,000 per share. Under the terms of the Series B Purchase Agreement, subject to the Company’s ability to maintain an effective registration statement for the Warrant Shares (as defined below), the Company may from time to time until July 19, 2013, present Optimus with a notice to purchase a specified amount of Series B Preferred Stock. Subject to satisfaction of certain closing conditions, Optimus is obligated to purchase such shares of Series B Preferred Stock on the 10th trading day after the date of the notice. The Company will determine, in its sole discretion, the timing and amount of Series B Preferred Stock to be purchased by Optimus, and may sell such shares in multiple tranches. Optimus will not be obligated to purchase the Series B Preferred Stock upon the Company’s notice (i) in the event the average closing sale price of the Company’s common stock during the nine trading days following delivery of such notice falls below 75% of the closing sale price of the Company’s common stock on the trading day prior to the date such notice is delivered to Optimus, or (ii) to the extent such purchase would result in the Company and its affiliates beneficially owning more than 9.99% of the Company’s outstanding common stock. The Series B Preferred Stock is only redeemable at the option of the Company as set forth in the Company’s Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock and not otherwise subject to redemption or repurchase by the Company in any circumstances.

Pursuant to the Series B Purchase Agreement, on July 19, 2010, the Company issued to an affiliate of Optimus a three-year warrant to purchase up to 40,500,000 shares of the Company’s common stock (the “Warrant Shares”), at an initial exercise price of $0.25 per share, subject to adjustment as described below. The warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Series B Purchase Agreement. On each tranche notice date, that portion of the warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the warrant may be paid (at the option of the affiliate of Optimus) in cash or by its issuance of a four-year, full-recourse promissory note, bearing interest at 2% per annum, and secured by a specified portfolio of assets. However, such promissory note is not due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Series B Preferred Stock issued or outstanding. In addition, the Company redeemed two hundred twenty-six (226) shares of Series B Preferred Stock held by the Investor for an aggregate redemption price of $3,141,004 consisting of (i) cash in an amount of $76,622 and (ii) cancellation of certain promissory notes issued by an affiliate of the Investor to the Company in the aggregate amount of $3,051,000 and accrued interest of approximately $13,382. This resulted in a net promissory note receivable of $9,998,210 as of October 31, 2011. The Company also recorded $50,401 and $485,812 in accrued interest on the promissory notes through the three months ended January 31, 2013 and the twelve months ended October 31, 2012, respectively. The value of the Promissory Note and Interest Receivable was $10,534,424 and $10,484,022 as of January 31, 2013 and October 31, 2012, respectively. The promissory bears interest at 2 % per annum which is credited directly to capital.

On April 4, 2011,the Company and Optimus entered into an amendment to the Preferred Stock Purchase Agreement dated July 19, 2010 between the Company and Optimus. Under the amendment Optimus remains obligated, from time to time until July 19, 2013, to purchase up to an additional 284 shares of non-convertible, redeemable Series B Preferred Stock, $0.001 par value per share at a purchase price of $10,000 per share upon notice from the Company to the Investor, subject to the satisfaction of certain conditions set forth in the Purchase Agreement.

In order to satisfy certain conditions set forth in the Preferred Stock Purchase Agreement that would allow the Company to require the Investor to purchase the remaining shares of Series B Preferred Stock under the Preferred Stock Purchase Agreement, the Amendment provides that, among other things, the Company will issue to the Holder a three-year warrant (the “ Additional Warrant ”) to purchase up to an additional 25,560,000 shares of the Company’s common stock, at an initial exercise price of $0.15 per share, subject to adjustment as described below. The Additional Warrant will become exercisable on the earlier of (i) the date on which a registration statement registering for resale the shares of the Company’s common stock issuable upon exercise of the Additional Warrant (the “ Warrant Shares ”) becomes effective and (ii) the first date on which such Warrant Shares are eligible for resale without limitation under Rule 144 (assuming a cashless exercise of the Additional Warrant). The Additional Warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Preferred StockPurchase Agreement. On each tranche notice date, that portion of the Additional Warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the Additional Warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the Additional Warrant may be paid (at the option of the Investor) in cash or by the Investor’s issuance of a four-year, full-recourse promissory note (each, a “ Promissory Note ”), bearing interest at 2% per annum, and secured by specified portfolio of assets. However, no Promissory Note will be due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Company’s Series B Preferred Stock issued or outstanding. The Additional Warrant also provides for cashless exercise in certain circumstances. If a “Funding Default” (as such term is defined in the Additional Warrant) occurs and the Additional Warrant has not previously been exercised in full, the Company has the right to demand surrender of the Additional Warrant (or any remaining portion thereof) without compensation, and the Additional Warrant will automatically be cancelled.

Holders of Series B preferred stock will be entitled to receive dividends, which will accrue in shares of Series B preferred stock on an annual basis at a rate equal to 10% per annum from the issuance date. Accrued dividends will be payable upon redemption of the Series B preferred stock or upon the liquidation, dissolution or winding up of our company. In the event the company redeems all or a portion of any shares of the Series B Preferred Stock then held by Optimus, Optimus shall apply, and the Company may offset, the proceeds of any such redemption to pay down the accrued interest and outstanding principal of the Promissory Note from Optimus.

As of January 31, 2013, the Series B preferred stock had a liquidation preference of $9,907,570 comprised of $10,000 per share plus the total of the cumulative accrued dividends in the amount of $2,507,570. At October 31, 2012 the Series B preferred stock had a liquidation preference of $9,722,570 comprised of $10,000 per share plus the total of the cumulative accrued dividends in the amount of $2,322,570. During the three months ended January 31, 2013 and 2012 and the period from March 1, 2002 (date of inception) to January 31, 2013, the Company accrued dividends of $185,000, $185,000 and $2,507,570 respectively.

On April 4, 2011, the Company and the Holder also entered into an Amended and Restated Security Agreement to ensure that any Promissory Note issued upon exercise of the Additional Warrant will be entitled to the benefits of the security and collateral provisions of the Security Agreement dated as of July 19, 2010.

During the three months ended January 31, 2013 and 2012, the Company did not sell any preferred shares to Optimus.

As of both January 31, 2013 and October 31, 2012, the Company continued to have 284 shares of its Series B Preferred Stock available for sale to Optimus at a gross purchase price of $10,000.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

FAIR VALUE

3 Months Ended

Jan. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

14. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii)knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

· Level 1 — Quoted prices in active markets for identical assets or liabilities

· Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities

· Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities

The following table provides the liabilities carried at fair value measured on a recurring basis as of January 31, 2013:

January 31, 2013	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $0.045 - $0.17 from October 2012 through December 2017	$	-	$		$	3,384,725	$	3,384,725


January 31, 2013
Short term Convertible Notes Payable at fair value
May 2012 Notes	$	-	$		$	807,960	$	807,960
Asher Notes – September & November 2012					$	426,173		426,173
Patton Note					$	185,426	$	185,426
JMJ Financial						427,730		427,730
Short-term convertible Notes Payable at fair value							$	1,847,289

October 31, 2012	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $0.053 - $0.17 from October 2012 through August 2017	$	-		$	$	434,136	$	434,136
Embedded Derivative Liability								-

October 31, 2012
Short term Convertible Notes Payable
May 2012 Notes	$	-	$	$	588,313	$	588,313
Hanover PIPE Notes – September & October 2012				$	362,791		362,791
Magna Exchange Note				$	333,086		333,086
Asher Note				$	150,687		150,687
French, Patton & Paterson Notes				$	208,664	$	208,664

Short-term convertible Notes and FV of Embedded Derivative						$	1,643,541

Common stock warrant liability:

	January 31, 2013 (Unaudited)
Beginning balance: October 31, 2012	$	434,136
Issuance of common stock warrants		1,460,867
Reclassification of warrant liability to equity		-
Exchange of warrants		-
Issuance of additional warrants due to anti-dilution provisions		3,274
Change in fair value		1,486,448

Balance at January 31, 2013	$	3,384,725

Convertible Note FV roll forward :

	January 31, 2013
	(Unaudited)
Beginning balance – October 31, 2012		1,643,541
Issuance of note		253,500
Transfer-out		(1,227,183	)
Change in Fair Value of Note		1,177,431
Ending balance – January 31, 2013		1,847,289

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUBSEQUENT EVENTS

3 Months Ended

Jan. 31, 2013

Subsequent Events [Abstract]

Subsequent Events [Text Block]

15. SUBSEQUENT EVENTS

Sale of stock under the Equity Enhancement Program

Under the Hanover Purchase Agreement, the Company may require Hanover Holdings to purchase up to $10.0 million of our common stock over a 24 month period (See Footnote 12 – Shareholders’ Equity).

On February 12, 2013, the Company issued 8,000,000 shares of our common stock to Hanover Holdings in connection with the settlement of a draw down pursuant to the Hanover Purchase Agreement, at a price of approximately $0.0644 per share. The per share price for such shares was established under the terms of the Hanover Purchase Agreement. We receive total net proceeds of $515,520 in connection with this draw down.

On March 1, 2013, the Company issued 12,000,000 shares of our common stock to Hanover in connection with the settlement of a draw down pursuant to the Purchase Agreement, at a price of approximately $0.095 per share. The per share price for such shares was established under the terms of the Purchase Agreement. The Company received total net proceeds of $1,134,000 in connection with this draw down.

Exercise of Warrants

On February 26, 2013, an accredited investor exercised 1,111,111 warrants at an exercise price of $0.085, resulting in net proceeds to the Company of $94,444.

Separation Agreement

On March 6, 2013, the Company announced the departure of Dr. John Rothman, the Company’s Executive Vice President of Clinical and Scientific Operations, effective March 1, 2013. On March 20, 2013, the Company entered into a Separation Agreement and General Release with Dr. Rothman, pursuant to which Dr. Rothman released the Company from all claims and agreed to continue to assist the Company as a consultant until February 28, 2014 in exchange for (i) being compensated on an hourly basis for certain project assignments as requested by the Company, (ii) receiving an aggregate of approximately $275,000, paid in installments over the course of the one year consulting period, and (iii) all of the options to purchase shares of our common stock held by Dr. Rothman being fully vested with the exercise period of such options being extended until March 1, 2015.

Office & Laboratory Lease

In April 2011, the Company entered into a Sublease Agreement and relocated the current offices and laboratory to an approximately 10.000 square foot leased facility in Princeton, NJ. Costs approximate $21,000 per month plus utilities. Utility costs are estimated to be approximately $7,200 per month and are capped at approximately $10,700 per month.

On March 13, 2013, the Company entered into a modification of the Sublease Agreement whereby all unpaid accrued lease amounts and future lease amounts through June 30, 2013, which the Company estimated to be approximately $450,000, would be satisfied by a payment in total of $200,000, with $100,000 paid on March 13, 2013 and $100,000 payable upon the consummation of a future capital raising transaction by the Company. In addition, lease payments for the period July 1, 2013 through November 30, 2015 will be reduced to a total of $20,000 per month.

Tonaquint

On March 14, 2013, the Company issued 21,327,990 shares of our common stock resulting from the partial cashless exercise of the warrant issued to Tonaquint during the three months ended January 31, 2013 and paid the Company an accelerated payment of $200,000 owed to the Company under the original agreement. Accordingly, the Company will record an increase to Short-term convertible notes account during the second fiscal quarter of 2013.

Brio Claim

On March 22, 2013, we were notified that a lawsuit against Advaxis had been filed by Brio Capital L.P., which we refer to as Brio, in the Supreme Court of the State of New York, County of New York, titled Brio Capital L.P. v. Advaxis Inc., Case No. 651029/2013, which we refer to as the Action. The complaint in the Action alleges, among other things, that Advaxis breached the terms of certain warrants to purchase shares of our common stock that we originally issued to Brio on October 17, 2007 and on June 18, 2009, each at an initial exercise price of $0.20 per share, and that Brio has suffered damages as a result thereof. Brio’s complaint seeks (i) a preliminary and permanent injunction directing us to issue to Brio 2,717,777 shares of our common stock, along with the necessary corporate resolutions and legal opinions to enable Brio to sell such common stock publicly without restriction; and (ii) damages of at least $500,000 (in an amount to be determined at trial), along with interest, costs and attorneys’ fees related to the Action. We believe the Action is entirely without merit, and we intend to vigorously defend against the Action.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Polices)

3 Months Ended

Jan. 31, 2013

Accounting Policies [Abstract]

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

	As of January 31,
	2013		2012
Warrants		125,154,408		140,976,812
Stock Options		44,287,424		45,057,424
Convertible Debt (using the if-converted method)		48,820,627		46,155,102
Total		218,262,459		232,189,338

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock Based Compensation

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Derivatives, Embedded Derivatives [Policy Text Block]

Derivative Financial Instruments

Debt Discount and Amortization Of Debt Discount [Policy Text Block]

Debt Discount and Amortization of Debt Discount

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Income Tax, Policy [Policy Text Block]

Income Taxes

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Jan. 31, 2013

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.

	As of January 31,
	2013		2012
Warrants		125,154,408		140,976,812
Stock Options		44,287,424		45,057,424
Convertible Debt (using the if-converted method)		48,820,627		46,155,102
Total		218,262,459		232,189,338

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Jan. 31, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consists of the following:

	January 31, 2013 (Unaudited)			October 31, 2012
Laboratory Equipment	$	287,518		$	287,518
Accumulated Depreciation		(214,042	)		(209,450	)
Net Property and Equipment	$	73,476		$	78,068

INTANGIBLE ASSETS (Tables)

3 Months Ended

Jan. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

The following is a summary of intangible assets as of the end of the following fiscal periods:


	January 31, 2013 (Unaudited)			October 31, 2012
License	$	651,992		$	651,992
Patents		2,466,119			2,422,409
Total intangibles		3,118,111			3,074,401
Accumulated Amortization		(699,349	)		(660,646	)
Intangible Assets	$	2,418,762		$	2,413,755

Schedule of Expected Amortization Expense [Table Text Block]

Estimated amortization expense for the next five years is as follows:

Year ended October 31,
2013			105,000
2014			140,000
2015			140,000
2016			140,000
2017			140,000

ACCRUED EXPENSES: (Tables)

3 Months Ended

Jan. 31, 2013

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

The following table represents the major components of accrued expenses:

	January 31, 2013 (Unaudited)		October 31, 2012
Salaries and other compensation	$	604,980	$	774,001
Clinical Trial		56,468		56,468
Vendors		77,512		77,512
Consultants		32,200		32,200
Financing costs		159,970		174,970
Legal		41,165		214,902
Interest Payable		55,046		28,859
Other		23,500		8,500
	$	1,050,841	$	1,367,412

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE (Tables)

3 Months Ended

Jan. 31, 2013

Convertible Notes Payable [Abstract]

Schedule of Debt [Table Text Block]

Convertible Notes payable consist of the following:

	January 31, 2013 (Unaudited)		October 31, 2012
October 2011 Note Financing		-		58,824
December 2011 Note Financing		-		131,928
May 2012 Note Financing		807,960		588,313
Bridge Notes		62,882		185,758
JMJ Financial		427,730		73,590
Hanover Holdings Note		280,034		362,791
Magna		-		333,086
Chris French		-		25,950
Asher		426,173		150,687
Yvonne Paterson		-		103,804
James Patton		185,426		78,909

Total Convertible Notes		2,190,205		2,093,640

Unamortized discount – Original Issue Discount (OID)		-		(4,541	)


Current Portion of Convertible Notes		2,190,205		2,089,099

DERIVATIVE INSTRUMENTS (Tables)

3 Months Ended

Jan. 31, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule Of Derivative Instruments Warrants [Table Text Block]

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange warrants-nonexercisable	$	0.15		34,791,156	October 2014	July 2012 Warrant Exchanges
Common Stock Purchase Warrant	$	0.15		3,578,949	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		1,453,553	October 2014-October 2015	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		2,213,234	January 2015-January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.085		2,777,777	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.1399-0.17		25,400,659	January 2013-April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		46,956	N/A	Vendor & Other
Common Stock Purchase Warrant	$	0.085-0.15		3,735,430	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant		0.045-0.085		1,919,764	October 2015-August 2017	August – September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant		0.15		23,676,930	December 2014	Tonaquint Promissory Note
		Subtotal:		99,594,408
Common Stock Purchase Warrant		TBD (1)		25,560,000	April 2014	Preferred Stock Agreement (4/04/2011)
		Grand Total		125,154,408

(1)

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange warrants-nonexercisable	$	0.15		34,791,156	October 2014	July 2012 Warrant Exchanges
Common Stock Purchase Warrant	$	0.15		3,578,949	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		1,453,553	October 2014-October 2015	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		2,213,234	January 2015-January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		2,777,777	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.1495-0.17		24,754 ,595	January 2013-April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		46,956	N/A	Vendor & Other
Common Stock Purchase Warrant	$	0.15		3,735,430	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant		0.0530-0.15		1,410,938	October 2015-August 2017	August – September 2012 Convertible Promissory Notes
		Subtotal:		74, 762,588
Common Stock Purchase Warrant		TBD (1)		25,560,000	April 2014	Preferred Stock Agreement (4/04/2011)
		Grand Total		100,322,588

(1)

Schedule Of Share Based Compensation Of Fair Value Of Options Using Black Scholes Option Pricing Model [Table Text Block]

In fair valuing the warrant liability, at January 31, 2013 and 2012, the Company used the following inputs in its Black-Scholes Model (BSM Model):

	(Unaudited) January 31, 2013			October 31, 2012

Exercise Price:		$ 0.045-0.17			$ 0.053-0.17

Stock Price		0.072			0.045

Expected term:		84-1769 days			81-1736 days

Volatility %		87.77%-180.89	%		66.51%-146.78	%

Risk Free Rate:		.06%-.26	%		.09-.56	%

STOCK OPTIONS : (Tables)

3 Months Ended

Jan. 31, 2013

Equity [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of changes in the stock option plan for three months ended January 31, 2013 is as follows:

	Number of			Weighted-Average
	Options			Exercise Price
Outstanding at October 31, 2012:		44,807,424		$	0.16
Granted		-		$	0.15
Exercised		-			—
Expired		(520,000	)		0.15
Outstanding at January 31, 2013		44,287,424		$	0.16
Vested and Exercisable at January 31, 2013		31,411,086		$	0.15

FAIR VALUE (Tables)

3 Months Ended

Jan. 31, 2013

Common Stock Warrant Liability [Member]

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following table provides the liabilities carried at fair value measured on a recurring basis as of January 31, 2013:

January 31, 2013	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $0.045 - $0.17 from October 2012 through December 2017	$	-	$		$	3,384,725	$	3,384,725


January 31, 2013
Short term Convertible Notes Payable at fair value
May 2012 Notes	$	-	$		$	807,960	$	807,960
Asher Notes – September & November 2012					$	426,173		426,173
Patton Note					$	185,426	$	185,426
JMJ Financial						427,730		427,730
Short-term convertible Notes Payable at fair value							$	1,847,289

October 31, 2012	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $0.053 - $0.17 from October 2012 through August 2017	$	-		$	$	434,136	$	434,136
Embedded Derivative Liability								-

October 31, 2012
Short term Convertible Notes Payable
May 2012 Notes	$	-	$	$	588,313	$	588,313
Hanover PIPE Notes – September & October 2012				$	362,791		362,791
Magna Exchange Note				$	333,086		333,086
Asher Note				$	150,687		150,687
French, Patton & Paterson Notes				$	208,664	$	208,664

Short-term convertible Notes and FV of Embedded Derivative						$	1,643,541

Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Common stock warrant liability:

	January 31, 2013 (Unaudited)
Beginning balance: October 31, 2012	$	434,136
Issuance of common stock warrants		1,460,867
Reclassification of warrant liability to equity		-
Exchange of warrants		-
Issuance of additional warrants due to anti-dilution provisions		3,274
Change in fair value		1,486,448

Balance at January 31, 2013	$	3,384,725

Convertible Note [Member]

Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Convertible Note FV roll forward :

	January 31, 2013
	(Unaudited)
Beginning balance – October 31, 2012		1,643,541
Issuance of note		253,500
Transfer-out		(1,227,183	)
Change in Fair Value of Note		1,177,431
Ending balance – January 31, 2013		1,847,289

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	3 Months Ended
	Jan. 31, 2013	Jan. 31, 2012
Total	218,262,459	232,189,338
Warrant [Member]
Total	125,154,408	140,976,812
Stock Options [Member]
Total	44,287,424	45,057,424
Convertible Debt Securities [Member]
Total	48,820,627	46,155,102

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jan. 31, 2013	Oct. 31, 2012
Laboratory Equipment	$ 287,518	$ 287,518
Accumulated Depreciation	(214,042)	(209,450)
Net Property and Equipment	$ 73,476	$ 78,068

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References + Details

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Textual)	3 Months Ended
	Jan. 31, 2013 USD ($)
Adjustments to Additional Paid in Capital, Warrant Issued	$ 1,700,000

- Definition

Increase in additional paid in capital due to warrants issued during the period. Includes also the proceeds of debt securities issued with detachable stock purchase warrants that are allocable to the warrants. These warrants qualify for equity classification and provide the holder with a right to purchase stock from the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7656322&loc=d3e4724-112606

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Warrant
-URI http://asc.fasb.org/extlink&oid=6528364

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 14
-Paragraph 16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	3 Months Ended		131 Months Ended
PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013
Depreciation expense	$ 4,592	$ 0	$ 214,040

INTANGIBLE ASSETS (Details) - USD ($)	Jan. 31, 2013	Oct. 31, 2012
License	$ 651,992	$ 651,992
Patents	2,466,119	2,422,409
Total intangibles	3,118,111	3,074,401
Accumulated Amortization	(699,349)	(660,646)
Intangible Assets	$ 2,418,762	$ 2,413,755

INTANGIBLE ASSETS (Details 1)	Jan. 31, 2013 USD ($)
2013	$ 105,000
2014	140,000
2015	140,000
2016	140,000
2017	$ 140,000

INTANGIBLE ASSETS (Details Textual) - USD ($)	3 Months Ended		131 Months Ended
INTANGIBLE ASSETS (Details Textual) - USD ($)	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013
Amortization expense of intangibles	$ 38,703	$ 35,409	$ 781,345
Minimum [Member]
Finite Lived Patents Expirations	2014
Maximum [Member]
Finite Lived Patents Expirations	2023

ACCRUED EXPENSES: (Details) - USD ($)	Jan. 31, 2013	Oct. 31, 2012
Salaries and other compensation	$ 604,980	$ 774,001
Clinical Trial	56,468	56,468
Vendors	77,512	77,512
Consultants	32,200	32,200
Financing costs	159,970	174,970
Legal	41,165	214,902
Interest Payable	55,046	28,859
Other	23,500	8,500
Accrued Liabilities, Current	$ 1,050,841	$ 1,367,412

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE (Details) - USD ($)	Jan. 31, 2013	Dec. 28, 2012	Nov. 12, 2012	Oct. 31, 2012	Sep. 11, 2012	Aug. 27, 2012	Aug. 02, 2012
Total Convertible Notes	$ 2,190,205			$ 2,093,640
Unamortized discount - Original Issue Discount (OID)	0			(4,541)
Current Portion of Convertible Notes	2,190,205			2,089,099
October 2011 Note Financing [Member]
Total Convertible Notes	0			58,824
December 2011 Note Financing [Member]
Total Convertible Notes	0			131,928
Unamortized discount - Original Issue Discount (OID)	(28,896)			(26,896)
May 2012 Note Financing [Member]
Total Convertible Notes	807,960			588,313
Bridge Notes [Member]
Total Convertible Notes	62,882			185,758
Jmj Financial [Member]
Total Convertible Notes	427,730	$ 100,000		73,590		$ 100,000
Hanover Holdings Note [Member]
Total Convertible Notes	280,034			362,791
Magna [Member]
Total Convertible Notes	0			333,086
Chris French [Member]
Total Convertible Notes	25,000			25,950
Asher [Member]
Total Convertible Notes	426,173		$ 153,500	150,687	$ 103,500
Yvonne Paterson [Member]
Total Convertible Notes	100,000			103,804
James Patton [Member]
Total Convertible Notes	$ 185,426			$ 78,909			$ 66,667

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE (Details Textual) - USD ($)				1 Months Ended	3 Months Ended
	Nov. 12, 2012	Aug. 02, 2012	May 14, 2012	Jul. 21, 2012	Jan. 31, 2013	Oct. 31, 2012	Mar. 10, 2013	Dec. 28, 2012	Dec. 06, 2012	Sep. 19, 2012	Sep. 11, 2012	Aug. 27, 2012
Convertible Notes Payable					$ 2,190,205	$ 2,093,640
Debt Instrument, Convertible, Conversion Price							$ 0.03
Debt Instrument, Maturity Date				Dec. 31, 2012
Other Noncash Expense					80,840
Issuance of notes				$ 250,000	9,561,416
Long-term Debt, Gross				$ 250,000			$ 250,000
Original Issue Discount, net of accreted interest					0	4,541
Long-term Debt					2,190,205	2,089,099
Debt Instrument, Interest Rate, Stated Percentage				33.00%
Warrant Liability					193,327	112,487
Interest Payable, Current					55,046	28,859
October 2011 Note Financing [Member]
Convertible Notes Payable					$ 0	58,824
Debt Conversion, Converted Instrument, Shares Issued					2,277,992
Other Noncash Expense					$ 70,000
October 2011 Note Financing [Member] \| Minimum [Member]
Debt Instrument, Convertible, Conversion Price					$ 0.025287
October 2011 Note Financing [Member] \| Maximum [Member]
Debt Instrument, Convertible, Conversion Price					$ 0.026017
December 2011 Note Financing [Member]
Convertible Notes Payable					$ 0	131,928
Debt Instrument, Convertible, Conversion Price					$ 0.027915
Debt Conversion, Converted Instrument, Amount					$ 170,589
Debt Conversion, Converted Instrument, Shares Issued					6,110,944
Other Noncash Expense					$ 104,000
Original Issue Discount, net of accreted interest					28,896	26,896
May 2012 Note Financing [Member]
Convertible Notes Payable					807,960	588,313
Junior Convertible Subordinated Convertible Notes [Member]
Convertible Notes Payable					$ 170,589	$ 186,000
Debt Instrument, Convertible, Conversion Price					$ 0.02596	$ 0.15
Percentage Of Common Stock Issuable Upon Conversion					6.00%
Debt Conversion, Converted Instrument, Amount					$ 11,765
Debt Conversion, Converted Instrument, Shares Issued					4,280,090
Other Noncash Expense					$ 106,000
Long-term Debt, Gross					$ 63,000
Minimum Percentage Of Warrant Received Coverage						23.00%
Maximum Percentage Of Warrant Received Coverage						75.00%
Debt Instrument, Maturity Date Range, Start					Oct. 19, 2011
Debt Instrument, Maturity Date Range, End					Oct. 22, 2011
Jmj Financial [Member]
Convertible Notes Payable					$ 427,730	$ 73,590		$ 100,000				$ 100,000
Debt Instrument Purchase Price								100,000				100,000
Percentage Of Common Stock Issuable Upon Conversion					70.00%
Debt Conversion, Converted Instrument, Amount					$ 100,000
Debt Conversion, Converted Instrument, Shares Issued					3,092,973
Other Noncash Expense					$ 328,000
Long-term Debt, Gross								115,000
Debt Instrument, Fair Value Disclosure					427,730			$ 125,000				$ 73,590
Other Noncash Income					96,000
Magna [Member]
Convertible Notes Payable					$ 0	333,086
Percentage Of Common Stock Issuable Upon Conversion					6.00%
Debt Conversion, Converted Instrument, Amount					$ 300,000
Debt Conversion, Converted Instrument, Shares Issued					10,124,026
Other Noncash Expense					$ 44,000
Long-term Debt					$ 58,824
Debt Instrument, Fair Value Disclosure						333,086
Magna [Member] \| Minimum [Member]
Debt Instrument, Convertible, Conversion Price					$ 0.0257
Magna [Member] \| Maximum [Member]
Debt Instrument, Convertible, Conversion Price					$ 0.0331
Asher [Member]
Convertible Notes Payable	$ 153,500				$ 426,173	150,687					$ 103,500
Debt Instrument Purchase Price	$ 150,000										$ 100,000
Percentage Of Common Stock Issuable Upon Conversion	65.00%										61.00%
Investors Minimum Beneficially Ownership Percentage	4.99%										4.99%
Other Noncash Expense					42,130	$ 47,187
Debt Instrument, Interest Rate, Stated Percentage	8.00%										8.00%
May 2012 Note Financings [Member]
Convertible Notes Payable			$ 953,333		$ 478,000
Debt Instrument Purchase Price			$ 715,000
Debt Instrument Discount Percentage			25.00%
Debt Instrument, Convertible, Conversion Price			$ 0.15		$ 0.025287	$ 0.025287
Percentage Of Common Stock Issuable Upon Conversion			50.00%
Debt Instrument, Maturity Date			May 18, 2013
Debt Conversion, Converted Instrument, Amount					$ 475,000
Debt Conversion, Converted Instrument, Shares Issued					18,784,353
Other Noncash Expense					$ 25,000
Issuance of notes			$ 454,680
Fair Value Of Interest and Additional Warrants Issued			$ 291,400
Exchange Agreement Warrants Excercise Price			$ 0.085
Interest and Debt Expense			$ 146,898
Unrealized Gain Loss On Note			$ 681,383
Hanover Holdings Notes [Member]
Convertible Notes Payable										$ 132,500
Debt Instrument Purchase Price										132,500
Hanover Holdings Notes [Member] \| Private Placement [Member]
Convertible Notes Payable									$ 100,000	132,500
Debt Instrument Purchase Price									$ 100,000	$ 132,500
Debt Instrument, Convertible, Conversion Price									$ 0.03
Percentage Of Common Stock Issuable Upon Conversion									4.99%
Issuance of notes					280,034
Long-term Debt, Gross					122,092
Original Issue Discount, net of accreted interest					37,125
Debt Instrument, Interest Rate, Stated Percentage									12.00%
Second Asher Note [Member]
Other Noncash Expense	$ 79,856
Chris French [Member]
Convertible Notes Payable					$ 25,000	$ 25,950
Debt Instrument, Convertible, Conversion Price					$ 0.045
Debt Instrument, Maturity Date					Oct. 26, 2015
Debt Conversion, Converted Instrument, Shares Issued					565,847
Other Noncash Expense					$ 21,000
Number Of Common Shares Issued For Debt					282,924
Exchange Agreement Warrants Excercise Price					$ 0.045
Interest Payable, Current					$ 633
Yvonne Paterson [Member]
Convertible Notes Payable					$ 100,000	103,804
Percentage Of Common Stock Issuable Upon Conversion					0.045%
Debt Instrument, Maturity Date					Oct. 26, 2015
Debt Conversion, Converted Instrument, Shares Issued					2,263,389
Other Noncash Expense					$ 32,000
Warrants To Purchase Of Common Stock					1,131,695
Exchange Agreement Warrants Excercise Price					$ 0.045
Interest Payable, Current					$ 2,532
James Patton [Member]
Convertible Notes Payable		$ 66,667			185,426	$ 78,909
Debt Instrument Purchase Price		$ 50,000
Debt Instrument Discount Percentage		25.00%
Debt Instrument, Payment Terms		0.75 for each $1.00
Debt Instrument, Convertible, Conversion Price		$ 0.025287
Percentage Of Common Stock Issuable Upon Conversion		50.00%
Debt Instrument, Maturity Date		Aug. 02, 2013
Investors Minimum Beneficially Ownership Percentage		4.99%
Other Noncash Expense					6,000
Exchange Agreement Warrants Excercise Price		$ 0.085
Debt Instrument, Fair Value Disclosure					14,044
Unrealized Gain Loss On Note					103,000
Interest Payable, Current					3,355
Third Magna Exchange Note [Member]
Debt Conversion, Converted Instrument, Amount					$ 111,111

NOTES PAYABLE-OFFICER: (Details Textual) - USD ($)	3 Months Ended		131 Months Ended
NOTES PAYABLE-OFFICER: (Details Textual) - USD ($)	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013	Mar. 10, 2013	Oct. 31, 2012	Jul. 21, 2012
Proceeds from notes payable	$ 0	$ 0	$ 250,000
Long-term Debt, Gross				$ 250,000		$ 250,000
Moore Notes [Member]
Debt Instrument, Interest Rate During Period	12.00%
Proceeds from notes payable	$ 6,000,000		3,800
Long-term Debt, Gross	491,000		491,000		$ 477,000
Interest Expense, Debt	$ 9,530	$ 8,257	$ 309,552

NOTES PAYABLE-OTHER: (Details Textual) - USD ($)		1 Months Ended
NOTES PAYABLE-OTHER: (Details Textual) - USD ($)	Mar. 10, 2013	Jul. 21, 2012	Jan. 31, 2013	Oct. 31, 2012
Interest Related To Promissory Note	$ 37,000	$ 37,000
Long-term Debt, Gross	$ 250,000	$ 250,000
Debt Instrument, Interest Rate, Stated Percentage		33.00%
Debt Instrument, Maturity Date		Dec. 31, 2012
Issuance of notes		$ 250,000	$ 9,561,416
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001	$ 0.001
Debt Instrument, Convertible, Conversion Price	$ 0.03

LONG-TERM CONVERTIBLE NOTE (Details Textual) - USD ($)	3 Months Ended
LONG-TERM CONVERTIBLE NOTE (Details Textual) - USD ($)	Jan. 31, 2013	Mar. 10, 2013	Dec. 13, 2012	Oct. 31, 2012	Jul. 21, 2012	Jan. 31, 2012	Oct. 31, 2011	Feb. 28, 2002
Convertible Notes Payable	$ 2,190,205			$ 2,093,640
Debt Instrument, Interest Rate, Stated Percentage					33.00%
Debt Instrument, Convertible, Conversion Price		$ 0.03
Cash	100			232		$ 588,442	$ 1,096,538	$ 0
Long-term Convertible Note (less unamortized OID of $40,566)	403,438			0
Original Issue Discount, net of accreted interest	0			$ 4,541
Tonaquint Note [Member]
Convertible Notes Payable			$ 890,000
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Debt Instrument, Convertible, Conversion Price			$ 0.16
Tonaquint Note [Member] \| Second Mortgage [Member]
Debt Instrument, Interest Rate, Stated Percentage			5.00%
Cash			$ 400,000
Secured Long-term Debt, Noncurrent			$ 200,000
Percentage Of Average Closing Bid Common Stock			80.00%
Tonaquint Note [Member] \| Original Issue Discount [Member]
Convertible Notes Payable	444,044
Secured Long-term Debt, Noncurrent	444,004
Long-term Convertible Note (less unamortized OID of $40,566)	$ 44,004
Debt Instrument Discount Percentage	9.10%
Interest Expense, Debt	$ 3,538
Original Issue Discount, net of accreted interest	$ 40,566

DERIVATIVE INSTRUMENTS (Details) - $ / shares

3 Months Ended

Jan. 31, 2013

Oct. 31, 2012

Amount

125,154,408

100,322,588

Common Stock Purchase Warrant [Member] | July 2012 Warrant Exchanges [Member]

Exercise Price

$ 0.15

Amount

34,791,156

Expiration Date

October 2014

Common Stock Purchase Warrant [Member] | May 2011 Convertible Debt Financing [Member]

Exercise Price

$ 0.15

Amount

3,578,949

Expiration Date

May 2015

Common Stock Purchase Warrant [Member] | October 2011 Convertible Debt Financing [Member]

Exercise Price

$ 0.15

Amount

1,453,553

Common Stock Purchase Warrant [Member] | October 2011 Convertible Debt Financing [Member] | Minimum [Member]

Expiration Date

October 2014

Common Stock Purchase Warrant [Member] | October 2011 Convertible Debt Financing [Member] | Maximum [Member]

Expiration Date

October 2015

Common Stock Purchase Warrant [Member] | December 2011 Convertible Debt Financing [Member]

Exercise Price

$ 0.15

Amount

2,213,234

Common Stock Purchase Warrant [Member] | December 2011 Convertible Debt Financing [Member] | Minimum [Member]

Expiration Date

January 2015

Common Stock Purchase Warrant [Member] | December 2011 Convertible Debt Financing [Member] | Maximum [Member]

Expiration Date

January 2016

Common Stock Purchase Warrant [Member] | May 2012 Convertible Debt Financing [Member]

Exercise Price

$ 0.085

$ 0.15

Amount

2,777,777

Expiration Date

May 2017

Common Stock Purchase Warrant [Member] | Bridge Notes [Member]

Amount

25,400,659

24,754,595

Common Stock Purchase Warrant [Member] | Bridge Notes [Member] | Minimum [Member]

Exercise Price

$ 0.1399

$ 0.1495

Expiration Date

January 2013

Common Stock Purchase Warrant [Member] | Bridge Notes [Member] | Maximum [Member]

Exercise Price

$ 0.17

Expiration Date

April 2015

Common Stock Purchase Warrant [Member] | Vendor & Other [Member]

Exercise Price

$ 0.15

Amount

46,956

Expiration Date

N/A

Common Stock Purchase Warrant [Member] | Placement Agent Convertible Debt Financing [Member]

Exercise Price

$ 0.15

Amount

3,735,430

Common Stock Purchase Warrant [Member] | Placement Agent Convertible Debt Financing [Member] | Minimum [Member]

Exercise Price

$ 0.085

Expiration Date

May 2014

Common Stock Purchase Warrant [Member] | Placement Agent Convertible Debt Financing [Member] | Maximum [Member]

Exercise Price

$ 0.15

Expiration Date

May 2017

Common Stock Purchase Warrant [Member] | August and September Convertible Promissory Notes [Member]

Amount

1,919,764

1,410,938

Common Stock Purchase Warrant [Member] | August and September Convertible Promissory Notes [Member] | Minimum [Member]

Exercise Price

$ 0.045

$ 0.0530

Expiration Date

October 2015

Common Stock Purchase Warrant [Member] | August and September Convertible Promissory Notes [Member] | Maximum [Member]

Exercise Price

$ 0.085

$ 0.15

Expiration Date

August 2017

Common Stock Purchase Warrant [Member] | Subtotal [Member]

Amount

99,594,408

74,762,588

Common Stock Purchase Warrant [Member] | Preferred Stock Agreement (4/04/2011) [Member]

Amount

^[1]

25,560,000

Expiration Date

^[1]

April 2014

Common Stock Purchase Warrant [Member] | Tonaquint Promissory Note [Member]

Exercise Price

$ 0.15

Amount

23,676,930

Expiration Date

December 2014

[1]	During December 2011, the Company unreserved for issuance shares related to the preferred stock warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

DERIVATIVE INSTRUMENTS (Details 1) - $ / shares	3 Months Ended
DERIVATIVE INSTRUMENTS (Details 1) - $ / shares	Jan. 31, 2013	Oct. 31, 2012
Stock Price:	$ 0.072	$ 0.045
Minimum [Member]
Exercise Price:	$ 0.045	$ 0.053
Expected term: (Days)	84 days	81 days
Volatility %	87.77%	66.51%
Risk Free Rate:	0.06%	0.09%
Maximum [Member]
Exercise Price:	$ 0.17	$ 0.17
Expected term: (Days)	1769 days	1736 days
Volatility %	180.89%	146.78%
Risk Free Rate:	0.26%	0.56%

DERIVATIVE INSTRUMENTS (Details Textual) - USD ($)	3 Months Ended			131 Months Ended
DERIVATIVE INSTRUMENTS (Details Textual) - USD ($)	Jan. 31, 2013	Oct. 31, 2012	Jan. 31, 2012	Jan. 31, 2013	Mar. 10, 2013
Class of Warrant or Right, Outstanding	125,154,408	100,322,588		125,154,408
Proceeds from exercise of warrants	$ 0		$ 411,765	$ 1,666,766
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001		$ 0.001	$ 0.001
Debt Instrument, Convertible, Conversion Price					$ 0.03
Common Stock [Member]
Class of Warrant or Right, Outstanding	90,363,252			90,363,252
Warrant Liability [Member]
Class of Warrant or Right, Outstanding	75,200,000			75,200,000
Exchange of warrants	$ 34,800,000
Derivative Liability, Fair Value, Gross Liability	3,400,000	$ 434,000		$ 3,400,000
Non Cash Warrant Expenses	2,950,000		2,950,000
Other Noncash Income	$ 900,000		$ 900,000
Warrants Subject To Anti Dilution Provisions	14,000,000
Warrant Liability [Member] \| Common Stock [Member]
Class of Warrant or Right, Outstanding	125,100,000	1,000,000		125,100,000
Derivative Liability, Fair Value, Gross Liability	$ 110,000,000	$ 85,200,000		$ 110,000,000
Warrant Equity [Member]
Class of Warrant or Right, Outstanding	15,100,000	15,100,000		15,100,000
Warrant Exchange [Member]
Exchange of warrants	$ 34,791,156
Warrants With Anti Dilution Provisions [Member]
Reduction In Warrant Outstanding Subject To Anti Dilution Provision	$ 14,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.14	$ 0.15		$ 0.14
Warrants Subject To Anti Dilution Provisions	110,000,000	14,000,000
Anti Dilution Provisions Additional Warrants Issuable		901,000
Anti Dilution Provisions Additional Warrants Exercise Price	$ 0.20
Probability Of Exercise Of Additional Warrants At Exercise Price One	0.1399%
Probability Of Exercise Of Additional Warrants At Exercise Price Two	0.10%
Warrants With Anti Dilution Provisions [Member] \| Minimum [Member]
Probability Of Exercise Of Additional Warrants At Exercise Price One	40.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two	60.00%
Warrants With Anti Dilution Provisions [Member] \| Maximum [Member]
Probability Of Exercise Of Additional Warrants At Exercise Price One	50.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two	50.00%
Warrant [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.045	$ 0.053		0.045
Warrant [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.17	$ 0.17		0.17
Exercise Of Warrants [Member]
Derivative Instruments, Gain (Loss) Recognized in Income, Net	$ 412,000
Exercises Of Warrants	$ 2,745,097
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.15			$ 0.15
Proceeds from exercise of warrants	$ 412,000

STOCK OPTIONS: (Details)	3 Months Ended
STOCK OPTIONS: (Details)	Jan. 31, 2013 $ / shares shares
Outstanding Number of Shares \| shares	44,807,424
Exercised Number of Shares \| shares	0
Cancelled or Expired Number of shares \| shares	(520,000)
Outstanding Number of Options \| shares	44,287,424
Vested & Exercisable Number of Shares \| shares	31,411,086
Outstanding Weighted-Average Exercise Price \| $ / shares	$ 0.16
Exercised Weighted-Average Exercise Price \| $ / shares	0
Cancelled or Expired Weighted Average Exercise Price \| $ / shares	0.15
Outstanding Weighted-Average Exercise Price \| $ / shares	0.16
Vested & Exercisable Weighted-Average Exercise Price \| $ / shares	$ 0.15

STOCK OPTIONS: (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		131 Months Ended
STOCK OPTIONS: (Details Textual) - USD ($)	Aug. 22, 2011	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013	Oct. 31, 2012	Aug. 13, 2012	Sep. 27, 2011
Vested & Exercisable Weighted Average Remaining Contractual Life In Years		1 year 9 months
Common stock, shares authorized		1,000,000,000		1,000,000,000	1,000,000,000
Options granted to consultants and professionals (in shares)		0	2,539,792
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		44,287,424		44,287,424	44,807,424
Non-cash charges to consultants and employees for options and stock		$ 369,923	$ 300,184	$ 5,349,969
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options		1,784,000		$ 1,784,000
Research and Development Expense [Member]
Non-cash charges to consultants and employees for options and stock		110,000	135,000
Employee Stock Ownership Plan (ESOP), Compensation Expense		263,000	300,000
General and Administrative Expense [Member]
Non-cash charges to consultants and employees for options and stock		$ 153,000	165,000
Employees and Consultants [Member]
Options granted to consultants and professionals (in shares)		17,120,000
Granted Weighted-Average Exercise Price		$ 0.15
Two Thousand and Four Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		2,381,525		2,381,525
Two Thousand and Five Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		5,444,000		5,444,000
Two Thousand and Nine Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		19,341,899		19,341,899
Two Thousand and Eleven Omnibus Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance							20,000,000
Common stock, shares authorized						45,000,000
Two Thousand and Eleven Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	85.00%
Common Stock, Capital Shares Reserved for Future Issuance	5,000,000
Proceeds from Stock Plans		$ 208,000	15,862
Income Tax Effects Allocated Directly to Equity, Employee Stock Options		$ 8,769	$ 2,200

COMMITMENTS AND CONTINGENCIES : (Details Textual)		1 Months Ended		3 Months Ended
COMMITMENTS AND CONTINGENCIES : (Details Textual)	May 10, 2010 USD ($) $ / shares shares	Apr. 30, 2011 USD ($) ft²	Jul. 31, 2009 USD ($)	Jan. 31, 2013 USD ($) $ / shares shares	Oct. 31, 2012 $ / shares shares	Jul. 24, 2012 USD ($)
Stock Price: \| $ / shares				$ 0.072	$ 0.045
Common stock, shares issued \| shares				493,415,628	394,804,165
Non Cash Income				$ 223,620
Proceeds From Net Operating Losses				725,000
Area of Land \| ft²		10,000
Pennsylvania [Member]
Option Exercise Fee Payable	$ 35,000
Stock issued	$ 70,000
Stock Issued (in shares) \| shares	388,889
Stock Price: \| $ / shares	$ 0.18
Historical Patent Costs	$ 462,000
Licensing Agreement Expenses				592,000
Numoda [Member]
Stock issued	$ 350,000
Stock Issued (in shares) \| shares	3,500,000
Due from Affiliates				7,600,000
Total Projected Agreement Cost			$ 12,200,000
Accounts Payable				$ 586,000
Numoda Socius Stock Issuance [Member]
Common stock, shares issued \| shares				24,681,069
Other Noncash Income				$ 615,000
Clinical Trail Services Settlement Claim						$ 2,888,860
Settlement Claim						1,800,000
Settlement Claim Towards Transaction Related Costs						$ 1,000,000
Office Laboratory Lease [Member]
Payments for Leasing Costs		$ 21,000
Cost of Utilities		7,200
Cost Of Utilities Per R E		$ 10,700
Lease Expiration Date		Nov. 29, 2015		Nov. 30, 2015
Expected Lease Operating Expenses		$ 38,000		$ 337,000
Operating Leases, Rent Expense		$ 54,000		$ 1,020,000

SHAREHOLDERS' EQUITY (Details Textual) - USD ($)		1 Months Ended						3 Months Ended			131 Months Ended
SHAREHOLDERS' EQUITY (Details Textual) - USD ($)	Apr. 04, 2011	Jan. 30, 2013	Dec. 20, 2012	Nov. 30, 2012	Oct. 26, 2012	Oct. 31, 2011	Jul. 19, 2010	Jan. 31, 2013	Oct. 31, 2012	Jan. 31, 2012	Jan. 31, 2013	Mar. 10, 2013	Jul. 21, 2012
Preferred stock, shares authorized								5,000,000	5,000,000		5,000,000
Debt Instrument, Interest Rate, Stated Percentage													33.00%
Common stock, par value (in dollars per share)								$ 0.001	$ 0.001		$ 0.001	$ 0.001
Preferred Stock, Amount of Preferred Dividends in Arrears								$ 185,000		$ 185,000	$ 2,507,570
Promissory Note Receivable								10,534,424	$ 10,484,022		10,534,424
Note receivable in connection with exercise of warrants								0		1,795,500	9,998,210
Other Noncash Expense								80,840
Net proceeds of issuance of common stock								$ 427,882		$ 0	$ 12,416,112
Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage							2.00%	2.00%			2.00%
Accrued Interest On Promissory Note								$ 50,401	$ 485,812
Note receivable in connection with exercise of warrants						$ 9,998,210
Warrant [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.045	$ 0.053		$ 0.045
Warrant [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.17	0.17		0.17
Common Stock [Member]
Stock Issued (in shares)			33,389,663					11,390,514
Legal Settlement Liability			$ 692,761
Hanover Purchase Agreement [Member]
Closing Sale Price Percentage					90.00%
Purchase Of Shares					10,000,000
Stock Issued (in shares)				3,500,000
Other Noncash Expense					$ 157,000
Net proceeds of issuance of common stock								$ 350,632
Ironridge Settlement [Member]
Stock Issued (in shares)			45,000,000
Common Stock Shares Returned		11,610,337
Common stock, par value (in dollars per share)			$ 0.001
Attorney Fees			$ 692,761
Series B Preferred Stock [Member]
Sale of Stock, Price Per Share	$ 10,000						$ 10,000	$ 10,000	$ 10,000		$ 10,000
Preferred stock, shares authorized							7,500,000
Closing Sale Price Percentage							75.00%
Outstanding Stock Percentage							9.99%
Preferred Stock Shares Available For Sale	284							284	284		284
Class Of Options Or Right Number Of Securities Called By Options Or Rights							40,500,000
Exercise Price Of Options							$ 0.25
Percentage Of Warrant Vest and Exercisable							135.00%
Common stock, par value (in dollars per share)	$ 0.001
Liquidation preference								$ 9,907,570	$ 9,722,570		$ 9,907,570
Preferred Stock, Liquidation Preference Per Share								$ 10,000	$ 10,000		$ 10,000
Preferred Stock, Amount of Preferred Dividends in Arrears								$ 2,507,570	$ 2,322,570
Preferred Stock redeemed (in shares)							226
Preferred Stock redeemed							$ 3,141,004
Stock Redeemed Or Called During Period Value Paid In Cash							76,622
Stock Redeemed Or Called During Period Value Paid In Extingushment Of Interest Debt Outstanding							13,382
Stock Redeemed Or Called During Period Value Paid In Extingushment Of Debt Outstanding							$ 3,051,000
Series B Preferred Stock [Member] \| Warrant [Member]
Debt Instrument, Interest Rate, Stated Percentage	2.00%
Additional Warrant In Percentage	135.00%
Stock Issued (in shares)	25,560,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.15

FAIR VALUE (Details) - USD ($)	Jan. 31, 2013	Oct. 31, 2012
Common stock warrant liability, warrants exercisable	$ 3,384,725	$ 434,136
Embedded Derivative Liability	1,847,289	1,643,541
May 2012 Notes [Member]
Embedded Derivative Liability	807,960	588,313
Asher Note [Member]
Embedded Derivative Liability	426,173	150,687
French, Patton & Paterson Notes [Member]
Embedded Derivative Liability	185,426	208,664
Jmj Financial [Member]
Embedded Derivative Liability	427,730
Hanover PIPE Notes [Member]
Embedded Derivative Liability		362,791
Magna Exchange Note [Member]
Embedded Derivative Liability		333,086
Fair Value, Inputs, Level 1 [Member] \| May 2012 Notes [Member]
Embedded Derivative Liability	0	0
Fair Value, Inputs, Level 1 [Member] \| Common Stock Warrant Liability [Member]
Common stock warrant liability, warrants exercisable	0
Fair Value, Inputs, Level 1 [Member] \| Embedded Derivative Liability [Member]
Common stock warrant liability, warrants exercisable		0
Fair Value, Inputs, Level 3 [Member] \| May 2012 Notes [Member]
Embedded Derivative Liability	807,960	588,313
Fair Value, Inputs, Level 3 [Member] \| Asher Note [Member]
Embedded Derivative Liability	426,173	150,687
Fair Value, Inputs, Level 3 [Member] \| French, Patton & Paterson Notes [Member]
Embedded Derivative Liability	185,426	208,664
Fair Value, Inputs, Level 3 [Member] \| Jmj Financial [Member]
Embedded Derivative Liability	427,730
Fair Value, Inputs, Level 3 [Member] \| Hanover PIPE Notes [Member]
Embedded Derivative Liability		362,791
Fair Value, Inputs, Level 3 [Member] \| Magna Exchange Note [Member]
Embedded Derivative Liability		333,086
Fair Value, Inputs, Level 3 [Member] \| Common Stock Warrant Liability [Member]
Common stock warrant liability, warrants exercisable	$ 3,384,725
Fair Value, Inputs, Level 3 [Member] \| Embedded Derivative Liability [Member]
Common stock warrant liability, warrants exercisable		$ 434,136

FAIR VALUE (Details 1) - Common Stock Warrant Liability [Member]	3 Months Ended
	Jan. 31, 2013 USD ($)
Beginning balance	$ 434,136
Issuance of common stock warrants	1,460,867
Reclassification of warrant liability to equity	0
Exchange of warrants	0
Issuance of additional warrants due to anti-dilution provisions	3,274
Change in fair value	1,486,448
Ending balance	$ 3,384,725

FAIR VALUE (Details 2) - Convertible Note [Member]	3 Months Ended
FAIR VALUE (Details 2) - Convertible Note [Member]	Jan. 31, 2013 USD ($)
Beginning balance	$ 1,643,541
Issuance of note	253,500
Transfer-out	(1,227,183)
Change in Fair Value of Note	1,177,431
Ending balance	$ 1,847,289

FAIR VALUE (Details Textual) - Warrant [Member] - $ / shares	3 Months Ended
	Jan. 31, 2013	Oct. 31, 2012
Expiration Date	October 2012 through December 2017	October 2012 through August 2017
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.045	$ 0.053
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.17	$ 0.17

SUBSEQUENT EVENTS (Details Textual)				1 Months Ended				3 Months Ended		131 Months Ended
SUBSEQUENT EVENTS (Details Textual)	Mar. 13, 2013 USD ($)	Mar. 06, 2013 USD ($)	Feb. 12, 2012 USD ($) $ / shares shares	Mar. 31, 2013 USD ($) shares	Mar. 22, 2013 USD ($) $ / shares shares	Feb. 26, 2013 USD ($) $ / shares	Apr. 30, 2011 USD ($) ft²	Jan. 31, 2013 USD ($) $ / shares shares	Jan. 31, 2012 USD ($)	Jan. 31, 2013 USD ($) $ / shares shares	Mar. 14, 2013 USD ($) shares	Mar. 01, 2013 $ / shares	Oct. 31, 2012 $ / shares shares
Stock Price: \| $ / shares								$ 0.072		$ 0.072			$ 0.045
Net proceeds of issuance of common stock								$ 427,882	$ 0	$ 12,416,112
Proceeds from exercise of warrants								$ 0	$ 411,765	$ 1,666,766
Area of Land \| ft²							10,000
Common stock, shares issued \| shares								493,415,628		493,415,628			394,804,165
Separation Agreement [Member]
General Release Agreement		$ 275,000
Office and Laboratory Lease [Member]
Area of Land \| ft²							10.000
Operating Leases, Rent Expense							$ 21,000
Estimated Utility Cost	$ 450,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months	100,000
Operating Leases, Future Minimum Payments, Due in Two Years	100,000
Accelerated Share Repurchases, Settlement (Payment) or Receipt											$ 200,000
Common stock, shares issued \| shares											21,327,990
Reduced Monthly Lease Payment Under Sublease Agreement	$ 20,000
Office and Laboratory Lease [Member] \| Minimum [Member]
Estimated Utility Cost							7,200
Office and Laboratory Lease [Member] \| Maximum [Member]
Estimated Utility Cost							$ 10,700
Sale Of Stock Under Equity Enhancement Program [Member] \| Hanover Purchase Agreement [Member]
Stock Issued During Period, Shares, Issued for Cash \| shares			8,000,000	12,000,000
Stock Price: \| $ / shares			$ 0.0644									$ 0.095
Net proceeds of issuance of common stock			$ 515,520	$ 1,134,000
Exercise Of Warrants [Member]
Proceeds from exercise of warrants						$ 1,111,111
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 0.085
Proceeds from Issuance of Warrants						$ 94,444
Brio Claim [Member]
Stock Price: \| $ / shares					$ 0.20
Loss Contingency, Damages Sought, Value					$ 500,000
Loss Contingency Damages Sought Shares \| shares					2,717,777